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ABSTRACT 
Background 
To investigate whether in-utero exposure to highly active antiretroviral treatment 
(HAART) is associated with low birth weight and/or preterm birth in a population 
of South African women with advanced HIV infection. 
 
Methods  
A retrospective observational study was performed on women with CD4 cell 
counts ≤250 cells/mm3 attending antenatal antiretroviral clinics at two clinics in 
Johannesburg between October 2004 and March 2007. Low birth weight (<2.5kg) 
and preterm birth rates (<37 weeks) were compared in those exposed versus 
unexposed to HAART during pregnancy. Effects of different HAART regimen and 
duration (<28 weeks or ≥ 28 weeks) were assessed.  
 
Results 
Among HAART-unexposed infants 27% (60/224) were low birth weight (LBW) 
compared to 23% (90/388) of early HAART-exposed and 19% (76/407) of late 
HAART-exposed infants (P=0.05). In the early HAART group, older maternal age 
was associated with LBW and higher CD4 cell count protective against LBW 
(AOR 1.06, 95% CI 1.00- 1.12 and AOR 0.58, 95% CI 0.46-0.73, P<0.001, 
respectively). HAART-exposed infants had an increased risk of preterm birth 
  vii 
(<37 weeks) (15% [138/946] versus 5% [7/147], p=0.001), with early (<28 weeks) 
nevirapine and efavirenz having the strongest associations with preterm birth 
(AOR 5.4, 95%CI 2.1-13.7, P<0.001 and AOR 5.6, 95%CI 2.1-15.2, P=0.001, 
respectively).  
 
Conclusion 
Among infants born to women with CD4 cell counts <250 cells/mm3, HAART 
exposure was associated with preterm birth, but not with low birth weight. More 
advanced immunosuppression was a significant risk factor for both LBW and 
preterm birth, highlighting the importance of earlier HAART initiation in pregnant 
women, both to optimize maternal health and to improve infant outcomes 
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CHAPTER 1 
 
1.0 INTRODUCTION 
 
1.1 CONTEXT  
The HIV epidemic in South Africa remains one of the fastest growing epidemics 
in the world. Currently about one third of all women attending antenatal clinics in 
the province of Gauteng are HIV seropositive [1]. This has a significant impact on 
women, children and their families in these communities. Not only are the unborn 
children at risk of acquiring HIV infection from their mothers, but the social, 
economic and health effects of HIV undermine the women’s’ ability to care for 
their families. In addition, AIDS is the leading cause of maternal mortality in 
South Africa [2]. This leaves many children orphaned, posing a huge burden on 
extended families and communities at large.  
 
Use of triple-combination antiretroviral regimens also known as Highly Active 
Antiretroviral Therapy (HAART) in HIV-infected pregnant women has been shown 
to decrease mother-to-child transmission of HIV (MTCT) [3]. Moreover, HAART 
use in pregnancy reduces maternal morbidity and mortality with consequent 
benefits for infants [4].However, the effects of HAART exposure on foetal and 
child development remain unclear. As an increasing number of South African 
women become pregnant while receiving HAART or are started on HAART 
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during pregnancy, it becomes important to understand effects of HAART on the 
foetus.  
 
1.2 LITERATURE REVIEW 
1.2.1 Ten years of conflicting studies: Does HAART exposure 
cause preterm birth? 1998 - 2008 
1998 - 2004 
The first association between preterm birth (birth before 37 weeks gestation) and 
combination antiretroviral treatment (HAART) during pregnancy was detected in 
1998,  in a small retrospective Swiss study of 30 women of whom 10 had preterm 
births [5]. Subsequently, in 2000, the combined results of the European 
Collaborative Study and Swiss Mother and Child HIV Cohort Study (3920 mother-
child pairs) showed that mothers treated with HAART containing a Protease 
Inhibitor (PI) were 2.6 fold more likely to have a preterm delivery than untreated 
mothers [6].  The European Collaborative (ECS) study group updated their 
findings in 2004 to include 4372 live births. An association between antenatal 
HAART use initiated pre-pregnancy and preterm birth (AOR 2.05, 95%CI 1.43, 
2.95), particularly severe preterm birth (before 34 weeks gestation) was 
demonstrated. The ECS also detected a high mortality rate associated with 
delivery at an early gestational age (7.37% at <34 weeks gestation) [7]. 
 
In contrast to the above, a 2002 combined cohort analysis of 7 US studies (US 
combined cohort [8]) among HIV-infected women (2123 women who received 
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some form of ART and 1143 women who did not receive ART) did not show an 
increased risk of low birth weight or preterm birth in women who received ART. 
Women who received PI-containing regimens were not more likely to have 
preterm births than those on other regimens [8]. The high prevalence of 
intravenous drug use (also a cause of preterm delivery) amongst the HIV-infected 
women from this study may have confounded outcomes [8]. 
 
2006 
In a 2006 article, Cotter et al attempted to answer the question: “Is antiretroviral 
therapy during pregnancy associated with an increased risk of preterm delivery, 
low birth weight, or stillbirth?” by conducting a prospective, single site study in 
Miami of 1337 HIV positive pregnant women from 1990 to 2002 [9]. Like the 
ECS, Cotter found that combination therapy with a PI was associated with an 
increased risk of preterm birth when compared to monotherapy or combination 
therapy without a PI. There was no difference in numbers of infants with low birth 
weight across the categories of therapy [9]. Interestingly, some of the patients 
from this study were part of the US combined cohorts study which found that 
ART was not associated with preterm birth[8].  Cotter explained this conflicting 
outcome was probably due to the way patients were selected for the multisite 
study, which excluded many of the Miami study patients and mentioned that a 
limitation of multisite collaborations is management of patients by different 
physicians at different sites, and the retrospective collection of data [9]. The 
Miami study aimed to investigate the relationship of ART and preterm birth in a 
single site managed by maternal-foetal medicine sub specialists adhering to strict 
  4 
protocols and unified standards of care[9]. Women who received PIs had given 
birth more recently, had lower CD4 cell counts and a more advanced stage of 
HIV disease which could have confounded pregnancy outcomes. However, after 
adjusting for year of delivery, race, prior preterm birth, lowest CD4 in pregnancy, 
CDC stage, duration of therapy, illicit drug use, smoking, alcohol use and 
presence of STD, only combination therapy with a PI was associated with an 
increased risk of preterm delivery (AOR 1.8 [CI,1.1-3.0]), compared with any 
other combination [9]. There was no increase in the rate of extreme preterm birth 
(<33 weeks) in women receiving a PI, possibly because of decreased exposure 
time [9].The authors believe that in pregnancy, PIs should be used with caution 
due to the increased morbidity and the increased risk of perinatal transmission of 
HIV associated with preterm birth [9, 10]. 
 
In response to this study, Tuomala and Yawetz reviewed the literature in a 2006 
editorial [11] in an attempt to tease out the issues causing discrepant results in 
the studies to date. See table 1.1 for studies included in the analysis: 
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Table 1.1 Comparison of studies included in Metanalysis by Tuomala et al [11] 
Study  Period Cohort 
size 
Location Association  
between 
HAART and 
preterm 
birth 
Limitations 
mentioned in 
article 
Advantages 
mentioned in 
the article 
Mandelbrot 
et al [12] 
1994-
1998 
1344 France No None 
mentioned 
None 
mentioned 
Swiss 
Cohort 
Study  
Lorenzi et al 
[5] 
1996-
1998 
37 Switzerland Yes None 
mentioned 
None 
mentioned 
ECS + Swiss 
[13] 
1986-
2000 
3920 Europe Yes  Did not control 
for prior 
preterm birth 
PIs typically 
reserved for 
more 
advanced HIV 
Did not control 
for HIV stage 
Controlled for 
duration of PI 
ECS [13] 1985-
2001 
2414 Europe Yes 
ECS 
Thorne et al 
[7] 
1986-
2004 
2669 Europe Yes 
7 US 
Combined 
cohorts 
Tuomala et 
al [8] 
1990-
1998 
3266 United 
States 
No Did not control 
for duration of 
PI  
PIs typically 
reserved for 
more 
advanced HIV 
Did not control 
for HIV stage 
Controlled for 
prior preterm 
birth 
WITS 
Tuomala et 
al [14] 
1990-
2002 
2543 United 
States 
No PIs typically 
reserved for 
more 
advanced HIV 
Multiple 
clinical sites 
Controlled for 
prior preterm 
birth 
Controlled for 
HIV stage 
Controlled for 
VL prior to 
delivery  
Morris et al 
[15] 
1997-
2001 
233 United 
States 
No None 
mentioned 
None 
mentioned 
Cotter et al 
[9] 
1994-
2006 
999 United 
States 
(Miami) 
Yes Did not control 
for VL prior to 
delivery 
Controlled for 
duration of PI 
Controlled for 
prior preterm 
birth 
Controlled for 
HIV stage 
Entire 
population from 
one site 
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In general, the analyses of data from European Cohorts demonstrated an 
association between preterm birth and combination ART, but those in United 
States and France showed no association [11]. The exception was the study by 
Cotter et al [9] which was the first US analysis which showed an association 
between combination ART and preterm birth. The discrepancy in results has 
been ascribed to inherent differences in patient population, differences between 
providers in choice of ART and use of elective caesarean section, and 
differences in study methodology and data analysis [11]. The ECS and Swiss 
Cohort studies did not control for prior preterm birth, a major risk factor for 
preterm birth. Studies which did control for prior preterm birth include: US 
combined cohorts [8], WITS (Women and Infants Transmission Study) [14] and 
Cotter [9]. Duration of PI use was controlled for in ECS but not the US combined 
cohort. Clinical disease stage, CD4 cell count and HIV load were controlled for in 
the studies by WITS and Cotter. These two studies had discrepant results with 
respect to association between preterm birth and ART, the WITS data showing 
that ART actually protected against preterm birth. The possible reasons for this 
finding include that the WITS study controlled for HIV load prior to delivery, and 
that the Cotter study protocol reserved PI use for more advanced stages of HIV 
disease and failure of virologic control. The ECS study also described reserving 
PIs for women with more advanced HIV disease. This link between PI-use and 
advanced HIV disease is considered an important confounding factor for preterm 
birth [11]. 
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Tuomala went on to explore the clinical implications of the studies’ findings [11]. 
The majority of preterm deliveries associated with combination ART occurred 
between 34 and 37 weeks gestation. Preterm births occurring late in the third 
trimester pose only small risks for neonatal mortality and morbidity in developed 
countries but the burden to developing countries with less access to neonatal 
care could be substantial. Preterm birth has also been associated with increased 
vertical transmission of HIV-1 [10] and significant costs to the health care system. 
Tuomala pointed out that a major flaw of all studies up to 2006 is that no study 
had controlled for stage of maternal HIV disease and satisfactorily addressed the 
issue of confounding of effect by indication for antiretroviral use during pregnancy 
[11]. A large randomized, controlled clinical trial aimed at carefully defining risks 
associated with combination ART regimens used during pregnancy by women 
receiving ART for foetal protection and whose HIV disease would not otherwise 
require therapy, is necessary. 
 
Later in 2006, among a population of 681 HIV-1-infected women on HAART in 
Latin America and the Caribbean, women who received a PI-containing ART 
regimen during pregnancy had a higher incidence of LBW and preterm birth 
compared to women who received one or two NNRTIs during pregnancy [16]. 
However, this association was not significant. This prospective study differed 
from previous ones in that the primary mode of HIV transmission in Latin America 
is heterosexual rather than through contaminated needles and intravenous drug 
use. As a result, the rate of alcohol and illicit substance use during pregnancy 
was found to be very low. This, as well as lower rates of elective caesarean 
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section, could have accounted for the lower overall rate of preterm birth and LBW 
among HIV-infected women seen in this cohort when compared with the North 
American and European studies, thus eliminating an important confounding risk 
factor for preterm birth [16]. With these factors eliminated, PI-exposure was not 
associated with LBW and preterm birth. 
 
2007 
A 2007 population surveillance study of 4445 pregnancies with antiretroviral 
therapy from 1990 to 2006 in the United Kingdom and Ireland demonstrated an 
increased risk of preterm birth associated with HAART, but not specifically 
protease inhibitors, versus monotherapy or dual therapy [17]. After adjusting for 
ethnicity, age, clinical status and intravenous drug use, women exposed to 
HAART were 1.51 times more likely to have a preterm infant (<37weeks) (CI 
1.19-1.93, P=0.001), and 2.34 times more likely to have an extremely premature 
infant (<35weeks) (CI 1.64-3.37, P<0.001) [17]. 
 
2007 Metanalysis Findings 
A 2007 Meta-analysis of 13 prospective cohorts and one retrospective study  
showed that HAART during pregnancy did not increase the risk of preterm birth 
(OR 1.13 CI 0.79-1.63) but that PI-containing combinations resulted in an odds 
ratio for preterm birth of 1.24 (95% CI 0.76-2.02) compared with combinations 
without PI [18]. The authors again commented that the use of PI-containing 
regimens might be more frequent in women with more advanced stage of HIV, in 
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itself a risk factor for preterm birth, thus accounting for some of the increased 
preterm birth observed in this group [18]. In the above studies, historical controls 
are mostly used for non-ART exposure. This may confound results as 
understanding of interventions for HIV-infected women during pregnancy have 
improved with time. A cut off of a gestational age of less than 37 weeks was used 
as the definition for preterm birth for most studies in the analysis. Data related to 
more severe degrees of preterm birth would be interesting to examine because of 
the increased preterm birth-related morbidity and mortality at earlier gestational 
ages [18]. The results of the meta-analysis could not be adjusted any potential 
confounding factors contributing to preterm birth because each study controlled 
for different factors. Factors which the authors would have liked to have adjusted 
for in the analysis included: maternal CD4 cell count, race, age, illicit drug, 
alcohol and tobacco use, previous preterm birth, duration of ART during 
pregnancy and year of delivery [18]. 
 
2008 
In 2008, data was published from a prospective study in Germany and Austria on 
the rate of adverse foetal outcomes in 183 mother-child pairs followed from 1990 
to 2001. PI-based therapy was associated with an increased risk of preterm 
delivery (AOR 3.40, 95%CI 1.13-10.2) compared with monotherapy after 
adjusting for race, maternal age, intravenous drug use, CD4 cell count at delivery 
and parity [19]. 
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At the 17th International Aids Conference in Mexico in August 2008, Claire 
Townsend presented a poster [20] to investigate why an association between 
preterm birth and use of HAART by HIV-positive mothers has been reported in 
some studies but not others. A comparison of three studies was undertaken 
namely: The Pediatric Spectrum of Disease (PSD) [21]; The European 
Collaborative Study (ECS) [7] and the National Study of HIV Pregnancy and 
Childhood (NSHPC) [17]. (See Table 1.2 for details of studies). After adjusting for 
history of injecting drug use, maternal ethnicity, maternal age (except PSD), HIV 
related symptoms at delivery (except ECS) and child’s birth year, the 
investigators found an association between form of ART (dual or triple therapy) 
and preterm birth compared to monotherapy across all 3 studies. HAART use 
(triple therapy) was associated with preterm birth in the ECS and NSHPC but not 
PSD studies (see table 1.2). Clayden commented that the reason HAART was 
associated with preterm birth in the UK and European studies and not the US 
study was possibly because  the US study participants had more factors 
associated with high background preterm birth rates [22]. She postulates that the 
effect of HAART on preterm birth can only be detected if the background preterm 
birth rate for patients on monotherapy is low, as in the UK  study where the 
preterm birth rate of patients on monotherapy was similar to the background rate 
of 6-8% seen in the HIV-negative UK population [22]. This highlights the 
importance of investigating the association of preterm birth and HAART in the 
context of the population of interest. This association has not been investigated in 
the South African context.  
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Clayden also pointed out the importance of the duration of HAART exposure in 
relation to gestational age at time of HAART initiation. This was not fully 
investigated in the three studies mentioned. She explained there is likely to be a 
lag between the initiation of therapy and any effect on the foetus. She highlighted 
the importance of investigating this further as it will impact the timing of HAART 
initiation for women who do not require HAART for their own health [22].  
Table 1.2: comparison of studies by Townsend et al [20] 
Study Name Authors 
Time 
period Location Study Type 
History of 
injecting 
drug use 
 n (%) 
Odds ratio for Preterm 
Delivery (95% CI)  
P value Summary of findings 
PSD - Paediatric 
Spectrum of 
Disease [21] 
Schulte J, 
Dominguez K, 
Sukalac T, 
Bohannon B, 
Fowler MG 
1990-
2004 US 
Medical 
record-
based 
cohort 
study 1189(13.1) 
Monotherapy 1.00                                        
Dual Therapy 0.79 
(0.64-0.97)  0.025                 
HAART 1.01 (0.87-
1.16) 0.931 
ART was associated 
with preterm birth 
compared to
monotherapy. HAART 
had no significant 
increase in preterm 
birth. 
ECS - European 
Collaborative 
Study [7] 
Thorne,C: 
Rudin,C: 
Newell,M et al 
1990-
2006 
26 centres 
in 9 
European 
Countries 
Consented 
Cohort 
Study 1460(35.5) 
Monotherapy 1.00                                        
Dual Therapy 0.94 
(0.65-1.37)0.765                  
HAART 1.64(1.3-
2.07)<0.001 
ART was associated 
with preterm birth 
compared to 
monotherapy. HAART 
showed significant 
increase in preterm birth 
NSHPC - National 
population-based 
surveillance study 
[17] 
Townsend,C: 
Cortina-
Borja,M; 
Peckham,C: 
Tookey,P 
1990-
2006 UK 
National 
population-
based 
surveillance 
study 295(4.4) 
Monotherapy 1.00                                        
Dual Therapy 1.04 
(0.59-1.83)0.888                  
HAART 1.47(1.15-
1.87)0.002 
ART was associated 
with preterm birth 
compared to 
monotherapy. HAART 
showed significant 
increase in preterm birth 
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Summary of published literature (1998-2008) 
Table 1.3: Major studies showing a link between preterm birth or low birth weight and 
HAART exposure: 
Study 
 
Year of publication Population Findings 
European Collaborative 
and Swiss Mother and 
child HIV cohort study 
[5] 
1998 3920 mother-child 
pairs in Europe 
Protease inhibitor 
exposure associated 
with preterm birth 
European Collaborative 
study [7] 
2004 4372 live births in 
Europe 
ART-initiation pre-
pregnancy associated 
with preterm birth 
especially extreme 
preterm birth 
Miami study, Cotter et 
al [9] 
2006 1337 women in 
Miami 
Protease inhibitor 
exposure associated 
with preterm birth 
National Population-
based surveillance 
study, Townsend et al 
[17] 
 
2007 4445 pregnancies 
in UK and Ireland 
HAART exposure 
associated with preterm 
birth especially extreme 
preterm birth 
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Table 1.4: Major studies showing no link between preterm birth or low birth weight and 
HAART exposure 
Study Year of publication Population Findings 
US combined cohort 
[8] 
2002 3266 women in 
the US 
No association 
between LBW or 
preterm birth and 
HAART exposure 
WITS [14] 2005 2543 women in 
the US 
Preterm birth 
decreased in 
association with 
HAART exposure  
Szyld et al [16] 
 
2006 681 women in 
Latin America 
and the 
Caribbean 
PI-exposure not  
associated with LBW or 
preterm birth compared 
to NNRTI exposure 
 Paediatric Spectrum 
of Diseases [21] 
2007 11 321 infants in 
the US 
HAART not  associated 
with preterm birth 
 
Studies to date have mainly taken place in developed countries where HAART is 
being used in pregnancy as a PMTCT intervention, regardless of maternal CD4 
cell count and stage of HIV disease, with the option of post-partum 
discontinuation of HAART [5, 7-9, 18]. Additionally in these published studies 
many women acquire HIV from IV drug use and many pregnant women smoke, 
confounding the preterm birth outcome. Further study of data representing 
different ethnic and geographical populations of pregnant HIV-infected women 
are necessary [18]. 
 
The exact PI used in previous studies is not  mentioned except in the studies by 
Lorenzi [5] and Cotter [9] which specify unboosted PIs such as nelfinavir and 
saquinavir as the main PIs used. The effects of in-utero exposure to boosted PIs, 
for instance Lopinavir boosted by Ritonavir (Kaletra®), have not been published. 
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1.2.2 African Literature 
There is limited data from Africa exploring HAART and birth outcomes. A study in  
Abidjan, Côte d’Ivoire in 2008 [23]  compared women eligible for HAART from 
two sequential cohorts -the ANRS Ditrame plus (March 2001- July 2008) and 
MTCT-plus projects (August 2003 – August 2007). The former cohort (175 
women) received short course ART for PMTCT (mainly short course AZT and 
single dose NVP) and the latter cohort (151 women) received HAART (Mainly 
AZT, 3TC and NVP). The rate of LBW was 22.3% in the HAART group and 
12.4% in the short course ART group (P=0.02).  HAART initiated before 
pregnancy (AOR 2.88, 95%CI 1.10- 7.51) and during pregnancy (AOR 2.12, 
95%CI 1.15-4.65) and low maternal BMI at delivery were associated with LBW 
[23]. Infants were followed up until 1 year of age and neither LBW nor maternal 
exposure to HAART was statistically associated with infant mortality in HIV-
uninfected infants [23].  Weaknesses of the study included the inability to 
determine preterm birth rates in the data set, the inability to examine the 
relationship between the duration of ART or HAART exposure and LBW and that 
confounding variables such as smoking, alcohol and illicit substance use were 
not taken into account. A strength of the study was that maternal WHO clinical 
stage and CD4 cell count were controlled for [23]. 
 
Another African study took place in four facilities in Botswana between October 
2007 and June 2008 [24, 25]. The study included 5676 live births, 1629 of which 
had an HIV positive mother, and 239 received HAART antenatally. In multivariate 
analysis, HAART was associated with small for gestational age (SGA) infants 
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and this association remained after adjustment for CD4 cell count. The risk of 
adverse birth outcome according to HAART regimen was not explored. 
Interestingly, the investigators also found that hypertensive complications at 
delivery were more common among women who received HAART from prior to 
the current pregnancy (P=0.02) [24, 25]. The possible link between hypertension, 
HAART and preterm birth is explored later in this dissertation. 
 
1.3 BACKGROUND  
1.3.1 Low birth weight 
Normal birth weight varies between 2.5kg and 4kg. Infants weighing less than 
2.5kg are classified as low birth weight (LBW), infants weighing less than 1.5kg 
as very low birth weight (VLBW) and infants weighing less than 1kg as extremely 
low birth weight (ELBW) [26].  
 
LBW contributes to infant and childhood morbidity and mortality. A direct 
correlation between the LBW rate and infant mortality rate in many countries has 
been found [26]. LBW and premature infants are at risk for multiple organ system 
complications, including respiratory, cardiovascular, haematologic, 
gastrointestinal, metabolic-endocrine, central nervous system and renal [26]. 
Among VLBW infants, morbidity is inversely related to birth weight. 
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Figure 1 Morbidity of VLBW infants according to birth weight 
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*Figure made using data from Nelson’s Textbook of Pediatrics [26] 
VLBW infants are at high risk for late sepsis (24%), intraventricular haemorrhage 
(11%), bronchopulmonary dysplasia (23%), necrotizing enterocolitis (7%) and 
prolonged hospitalisation (45-125 days). Foetal growth has also been identified 
as a risk factor for cognitive disability and neurodevelopmental impairment later 
in childhood. Poor postnatal growth is an important association of preterm and 
LBW infants [26-28]. 
 
Substantial resources at hospital level are required to take care of LBW and 
premature infants. These infants, particularly if they are VLBW or extremely 
premature, often require prolonged admission in an intensive care unit (ICU) for 
parenteral nutrition, fluid balance, respiratory support, thermal regulation, 
treatment and monitoring of infections and referral for specialized care [26]. This 
places a burden on the already stretched health care systems of developing 
countries. 
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Epidemiology and Causation of low birth weight 
Low birth weight is caused by preterm birth or intrauterine growth restriction 
(IUGR) or both. Preterm birth is the predominant cause of LBW in industrialized 
countries whereas developing countries have IUGR as the predominant cause 
[26]. Rates of LBW are lower in industrialized countries than developing 
countries. When LBW rates are more than 10%, IUGR is often the predominant 
cause of LBW [26]. In 2007 according to UNICEF, South Africa had a LBW rate 
of 15% [29]. This is slightly higher than the USA’s LBW rate of 12-13%, which 
has increased over the last 10 years due to assisted reproductive technology 
[28]. Other developed countries in Europe report LBW rates as low as 5-9% [28].  
 
LBW due to IUGR can also be divided into asymmetrical and symmetrical growth 
restriction. In asymmetrical growth restriction the infant’s weight is affected more 
than the skeletal structure which results in the weight and length being on a lower 
centile (according to gestational age) than the head circumference. This is 
associated with factors which affect foetal growth late in pregnancy. Symmetrical 
growth restriction is caused by factors which operate over the entire pregnancy 
and affects the head circumference, length and weight of the infant equally [26]. 
 
It is difficult to completely separate factors associated with preterm birth and 
IUGR because both have multifactorial aetiologies which involve complex 
interactions between foetal, placental, uterine and maternal factors.  
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LBW has been linked to black race, low or high maternal age, poor economic 
status, low educational status, single marital status, small parental size, interval 
between pregnancies of less than six months and mother’s parity more than four. 
Male infants are about 100g heavier than female infants. Socio-economic 
deprivation of the parents has been specifically linked to a slower rate of foetal 
growth late in pregnancy resulting in asymmetrical growth restriction [26-28]. 
 
1.3.2 Preterm birth 
Causation of preterm birth 
Preterm birth of infants with a weight that is appropriate for gestational age is 
associated with factors which abruptly interfere with the ability of the uterus to 
retain the foetus. These factors could operate by causing rupture of amniotic 
membranes, stimulating uterine contractions or premature separation of the 
placenta. A major cause of preterm birth is overt or asymptomatic bacterial 
infection of the amniotic fluid and membranes. In general causes can be divided 
as follows [26, 28]: 
1) Foetal - multiple gestation, foetal distress, erythroblastosis and non 
immune hydrops. 
2) Placental - placenta previa and abruptio placentae.  
3) Uterine - Incompetent cervix and bicornuate uterus. 
4)  Maternal –  
o pre-eclampsia 
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o chronic medical condition (e.g. malnutrition, obesity, hypertension, 
diabetes, thyroid disease, anaemia and asthma) 
o infection (amniotic infections, genital tract infections [especially 
bacterial vaginosis, Chlamydia, gonorrhoea and syphilis] and systemic 
infections [including HIV and malaria] ) 
o substance use (smoking, heavy alcohol use, illicit substance use) 
o  psychological stress. 
5) Other - premature rupture of membranes, polyhydramnios, iatrogenic, 
trauma.  
 
1.3.3 Intrauterine growth restriction 
IUGR results in the birth of infants who have lower weights at birth than would be 
expected for their gestational age. Small for gestational age (SGA) is defined as 
having a birth weight which falls below the 10th centile of the weight range for a 
particular gestational age. 
 
Causation of intrauterine growth restriction 
IUGR is associated with medical conditions which interfere with the growth of the 
foetus over a period of time. There is much overlap between the causes of IUGR 
and preterm birth [26]. 
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The causes of IUGR can be divided as follows [26, 27]: 
1) Placental - low placental weight or surface area, placentitis, infarct, 
tumour, separation, twin-twin transfusion. 
2) Maternal - infection, hypertension, hypoxemia, malnutrition, chronic 
disease, drugs, alcohol, smoking, environmental exposures. 
3) Foetal- chromosomal abnormalities, chronic infections, congenital 
anomalies, irradiation, multiple gestation, insulin deficiency.  
 
1.3.4 Preterm birth associated with HAART exposure 
Immune modulation and preterm birth 
A normal pregnancy is characterized by an increase in Th2 cytokines and 
suppression of Th1 cytokine production. This is because the feto-placental unit 
produces Th2 cytokines throughout pregnancy which inhibit maternal Th1 
cytokines, protecting the pregnancy [30, 31]. The progression of HIV disease is 
also characterized by a shift from Th1 to Th2 cytokine production [32]. HAART 
counteracts this cytokine shift [32]. It has been hypothesized that the increased 
risk for preterm delivery observed in HIV-infected, HAART-exposed women is 
mediated through changes in the cytokine environment in pregnancy [33]. Fiore 
et al [33] measured levels of interleukin 2 (IL-2) and interleukin 10 (IL-10), as well 
as other cytokines (IL-2-PHA, IL-2-Env, IL-10-PHA and IL-10-Env), three times 
during pregnancy in 49 HIV-infected women. The results showed that HAART 
use in pregnancy was associated with increased IL-2 (Th1) and decreased IL-10 
(Th2). HAART use and IL-10-Env slopes were not significantly associated with 
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preterm birth risk, but each unit increase in the IL-2-PHA slope was associated 
with an 8% increased risk of preterm birth (AOR, 1.08: 95% CI, 1.0-1.17: 
P=0.005). The authors concluded that although HAART had significant benefits 
in delaying HIV progression and preventing mother-to-child transmission of HIV, 
it may be associated with negative pregnancy outcomes due to immune 
modulation. 
 
Pre-eclampsia and preterm birth 
Pre-eclampsia was an uncommon complication of pregnancy in the pre-HAART 
era when HIV positive women were found to be less at risk for pre-eclampsia 
than their negative counterparts [34]. Pregnant women on HAART are however 
as likely to experience pre-eclampsia as the general population [35]. One 
European survey of 36 hospitals from 11 countries has identified pre-eclampsia 
as the most common adverse event in HAART-exposed women [36]. A Spanish 
study investigated this further by looking for trends in prevalence of pre-
eclampsia and foetal death over 18 years [37]. The study showed a significant 
increase in the rate of pre-eclampsia in HIV-infected women over a 15 year time 
period (1985 to 2000) and HAART exposure prior to pregnancy was identified as 
a risk factor for pre-eclampsia. [37] 
Among the 12 HAART-exposed patients in the Spanish study who developed 
pre-eclampsia or foetal death, 4 (33%) were born before 34 weeks of gestation, 1 
(8%) was born between 37 and 34 weeks, and 7 (58 %) were born at or after 37 
weeks [37]. The study concluded that HAART prior to pregnancy was associated 
with a higher risk for pre-eclampsia and foetal death. Insulin resistance and 
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endothelial inflammation were identified as potential underlying mechanisms [37]. 
Although not specifically investigated, the same process could lead to increased 
risk of preterm deliveries in HAART-exposed women.   
 
Hormonal Modulation 
PIs have been shown to decrease the plasma concentrations of exogenously 
administered ethinylestradiol by PI induction of the hepatic P450 cytochrome 
enzyme system [38]. It is possible that PIs also disrupt oestrogen and 
progesterone metabolism in pregnancy causing preterm labour [39]. 
 
1.4 THE SOUTH AFRICAN CONTEXT 
Compared with other middle-income countries, the South African standard of 
care for PMTCT prior to 2008 was suboptimal. Only women with CD4 cell counts 
of 200cells/mm3 or less or WHO clinical stage IV disease qualified for HAART, as 
specified by the Department of Health Policy Guidelines [40].  Women who did 
not qualify for HAART received a single dose of nevirapine (NVP) to be taken at 
onset of labour followed by a single dose of NVP to the infant within 72 hours of 
birth [40]. Paradoxically, women at a more advanced stage of disease were 
therefore less likely to transmit HIV to their infants because they accessed 
HAART [41]. A 2005 JAIDS paper presenting results from Rahima Moosa Mother 
and Child Hospital (RM) in Johannesburg documented this paradoxical situation 
[41]. 
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South African pregnant women who access HAART differ in important ways from 
those studied in the Northern Hemisphere. Firstly women receiving HAART 
antenatally in South Africa are at a later stage of HIV disease than their 
counterparts in high-income countries. Secondly, HIV Clade C predominates in 
South Africa as opposed to Clade B in Western Europe and North America. 
Lastly, HIV infection among South African women is acquired through 
heterosexual contact rather than through intravenous drug use which was 
historically the main mechanism of transmission in Europe and America.  
 
Additional evidence of the impact of HAART exposure on infants in our setting is 
required.  
 
1.5 STUDY OBJECTIVES 
The study aims to test the null hypothesis that HAART is not associated with 
preterm birth. It is designed to determine whether an association exists between 
HAART and various birth outcomes (preterm birth, low birth weight and others) 
and to determine the strength of the association. It was conducted in women with 
low immunity in a South African context. 
The specific study objectives are: 
1) To compare gestation at delivery and birth weights of infants exposed to 
HAART during pregnancy with those without such exposure. 
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2) To compare gestation at delivery and birth weights of infants exposed to 
HAART before 28 weeks gestation (early HAART) and those exposed to 
HAART at or after 28 weeks  gestation (late HAART). 
3) To compare gestation at delivery and birth weights of infants exposed to 
PI-based (lopinavir/ritonavir), NVP-based (nevirapine) and EFV-based 
(efavirenz) regimens. 
 
1.6 ORGANISATION OF THE THESIS 
The remainder of this thesis will attempt to explore the impact of in-utero HAART 
exposure on infants.  
 
The methods section will explain the context of study clinics, explain the selection 
of study participants, define the variables and detail the study design. 
 
The results section will systematically present the study findings covering the 
following sections: 
1. Phase 1: Comparison of study groups in terms of demographics and 
maternal health status. 
2. Phase 2: Comparison of study groups in terms of pregnancy 
characteristics and infant outcomes. 
3. Phase 3: Association of study variables with low birth weight and preterm 
birth among study infants.  
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4. Phase 4: Multivariate logistic regression analysis on the risk factors of 
LBW and preterm birth in study infants. 
 
The discussion section will attempt to explain the study’s findings in the context 
of the current literature and highlight study limitations.  
 
The conclusion will answer the objectives of the study and highlight the relevance 
of the study’s findings.  
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CHAPTER 2 
 
2.0 METHODS 
 
2.1 BACKGROUND 
Antenatal HIV clinics of Rahima Moosa (RM) and Charlotte Maxeke 
Johannesburg Academic (JH) are main referral centres for HIV-infected pregnant 
women.  Women attending Antenatal HIV clinics constitute an ongoing cohort in 
which HIV-infected women are enrolled and are observed in accordance with 
standard clinical and laboratory practice of the South African National HIV 
programme [40, 42]. Using the patient records, we conducted a retrospective 
observational study. Findings of previous analyses of this cohort have been 
presented elsewhere [41, 43-46]. 
 
2.1.1 Description of study hospitals 
RM is a secondary level academic hospital which has a midwife run antenatal 
clinic for uncomplicated pregnancies as well as an obstetrician run antenatal 
clinic for complicated pregnancies.  JH is a tertiary level academic hospital which 
mainly manages referrals of complicated pregnancies.  
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Description of study clinics 
The antenatal HIV clinics of Rahima Moosa (RM) and Charlotte Maxeke 
Johannesburg Academic (JH) were offering the following services at the time of 
the study: 
For all pregnant women: 
1) Provider-initiated HIV testing and counselling  
2) Essential antenatal care  
For all HIV-infected pregnant women 
1) CD4 cell count testing  
2) HIV Wellness Counselling and implications/interpretation of CD4 cell 
counts 
3) Counselling on infant feeding choices/options 
4) Participation in support group for HIV positive pregnant women 
 
For HIV-infected women who do not qualify for HAART:  
1) Provision of single dose-NVP  
2) Counselling on the signs of labour and use of NVP 
3) Referral to postnatal HIV clinic for infant diagnosis. 
 
For the women who qualified for HAART (HAART-exposed) 
1) Counselling on benefits of HAART to mother and infant 
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2) Counselling on side-effects of HAART 
3) Adherence counselling –the importance of taking HAART correctly as 
prescribed 
4) Baseline blood tests according to protocol  
5) Initiation of HAART 
6) Follow-up of patients on HAART fortnightly for women on nevirapine- 
based HAART for the first 4 weeks, monthly for lopinavir/ritonavir-based 
HAART. Women are followed up until approximately ten weeks post 
partum.  
7) Referral to post natal clinic for infant diagnosis and infant formula 
collection (when applicable). 
8) Referral of mother to Adult HIV clinic once infant has been delivered. 
(Mostly Helen Joseph Hospital, JH, Witkoppen Clinic or Hillbrow 
Community Health Centre.) 
 
The Postnatal (Infant follow-up) HIV clinic of RM Hospital was offering the 
following services: 
1) Maternal CD4 cell count and plasma Viral Load (VL) repeated as per 
guidelines. 
2) Adherence monitoring of women on HAART. 
3) For women not yet on HAART who qualify – initiation on HAART at the 
postnatal clinic or referral to an accredited ARV site. 
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4) Infant formula distribution. 
5) Infant clinical examination for stigmata of HIV and other abnormalities at 6 
weeks post birth. 
6) Trimethoprim/sulphethoxazole (Co-trimoxazole) prophylaxis provision to 
infant pending HIV result. 
7) Infant HIV PCR drawn and first clinical assessment at 6 weeks of age. 
8) Infant reassessed at 10 weeks of age and results of PCR provided to the 
caregiver. 
9) Infant  HIV diagnosis once clinical and laboratory tests conferred [47]. 
10) Referral of infants testing HIV positive to a Paediatric HIV clinic.  
 
A similar postnatal clinic at JH was started during the study period but patients 
were not recruited from this clinic.  
 
The study did not involve any further clinical or laboratory interventions over and 
above the services currently offered by the clinics. The study used data which 
was routinely collected from the records of clinic patients for the clinic data base 
or obtained retrospectively from their hospital records. 
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2.2 STUDY PARTICIPANTS 
The study included all eligible HIV-positive women attending HIV antenatal clinics 
of RM and JH and the HIV postnatal clinic of RM who gave birth from October 
2004 to March 2007, and their infants. The time period was chosen because the 
clinics began collecting data from October 2004 and the protocol was submitted 
for ethics evaluation in April 2007.  
 
2.2.1 Inclusion and exclusion criteria 
Inclusion criteria 
1) Confirmed HIV- infected – either by Rapid HIV test or HIV ELISA test. 
2) Presentation to the study clinic during pregnancy or less than 2 months 
post partum. 
3) CD4 cell counts during pregnancy or within 3 weeks post partum of less 
than or equal to 250cells/mm3. 
4) Singleton pregnancies. 
5) Verbal or written consent given for inclusion in the clinic data base. 
 
Exclusion criteria 
1) CD4 cell count more than 250 cells/mm3. 
2) Multiple births 
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2.2.2 Participant grouping 
Women in the study were divided according to the presence (HAART-exposed) 
or absence (HAART-unexposed) of HAART exposure during pregnancy. The 
HAART-exposed group was further divided according to the hospital they 
attended – JH or RM hospitals. HAART-exposed women were also divided 
according to those who started HAART before 28 weeks of pregnancy (early 
HAART) and those who started HAART at or after 28 weeks (late HAART).  
 
For each group the key measurable outcomes included birth weight and 
gestation at delivery. Other associated variables were also analysed. 
 
Women were further stratified into those with infant’s HIV PCR status known or 
unknown. Those with known PCR status were divided into positive and negative 
status. The group with negative PCR status were then analysed for associations 
of study variables with low birth weight. Those with unknown or  positive status 
were removed to control for the effect of in-utero HIV transmission on birth weight 
[48].  
 
HAART-exposed group 
Most women who received HAART from the study clinics had CD4 cell counts 
below 250cells/mm3 due to clinic protocols which were based on Department of 
Health Guidelines at the time [40]. The few women on HAART with CD4 cell 
counts above 250cells/mm3 were excluded from this study 
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Protocols for initiation of HAART to pregnant women at the hospitals differed. At 
RM hospital, pregnant women were initiated on PI-based HAART, namely 
lopinavir/ritonavir combination (Kaletra®), stavudine (D4T) and lamivudine (3TC) 
as first line therapy. nevirapine (NVP), D4T and 3TC or efavirenz (EFV), D4T and 
3TC and were reserved for women with contra-indications to lopinavir/ritonavir.  
 
At JH hospital, first line therapy was NVP, D4T and 3TC, and the other regimens 
mentioned were used for patients with contra-indication to NVP. In both hospitals, 
EFV was initiated mainly when pregnant women were receiving concomitant TB 
treatment (Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) because of drug 
interactions between TB drugs and lopinavir/ritonavir or NVP.  EFV was only 
initiated beyond the first trimester of pregnancy due to the potential teratogenic 
effects of EFV on foetal neural tube development [49]. Some women in the study 
were on EFV at the time of presentation at study clinics. Both hospitals followed 
the protocol of changing the EFV to lopinavir/ritonavir if women presented in the 
first trimester. Women who presented after the first trimester were left on EFV but 
underwent close foetal monitoring including ultrasound examinations to detect 
foetal anomalies. No foetal anomalies were detected in this group of women in 
either hospital.  
 
The HAART-exposed group was divided according to first regimen used in 
pregnancy– NNRTI-based (NVP-based or EFV-based) or PI-based. The purpose 
of these divisions was to compare the groups in terms of demographics, possible 
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confounding variables which could inadvertently cause preterm birth and to 
compare the birth outcomes of each exposure group. 
 
Most women in the HAART-exposed group accessed antenatal HIV care at the 
study clinics ante partum (see figure 2). Most HAART-unexposed women 
presented to the study clinics post partum for infant diagnosis. 
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Figure 2 Flow of patients through antenatal and postnatal HIV services to indicate points 
of entry into the study (highlighted in yellow) 
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HAART-unexposed group 
The unexposed group was drawn from HIV-infected women who did not receive 
HAART during pregnancy – most having received single dose nevirapine and a 
few having had no PMTCT opportunity. This control group consisted of HIV 
positive HAART-unexposed women with CD4 cell counts below 250cells/mm3 
during pregnancy or within three weeks of delivery. 
 
Most of the HAART-unexposed group members had missed the opportunity for 
HAART because they were identified as HIV positive during admission for 
delivery and referred to the postnatal clinic where they were found to have low 
CD4 cell counts.  At the time of the study, only the RM hospital had a dedicated 
postnatal clinic for follow-up of infants exposed to HIV, therefore all of the 
HAART-unexposed women were from RM hospital. The reasons for their missed 
opportunities for HAART included: 
 Women who had not attended antenatal clinic. 
 Women who had attended an antenatal clinic other than the study clinics 
but had not been diagnosed for HIV by the clinic due to patient refusal or 
poor health systems. 
 Women who had attended an antenatal clinic other than the study clinics 
and had been diagnosed for HIV but had not been staged using a CD4 
cell count due to patient refusal or failure of the health system. 
 Women who had attended an antenatal clinic other than the study clinics 
and had been diagnosed for HIV and found to have a low CD4 cell count 
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but had not initiated HAART due to patient refusal or health system 
failure. 
 Women who had attended a study clinic ante partum but had refused HIV 
diagnosis, HIV staging or HAART initiation. 
 Women who had attended a clinic ante partum, and qualified for HAART 
initiation but had failed to initiate HAART before delivery of the infant due 
to other urgent health concerns causing unavoidable delays.  
 
2.3 STUDY VARIABLES 
Using record review, we conducted a retrospective observational cohort study. 
The records of the women-infants pairs were reviewed to extract information on 
the following variables:  
Participant grouping: 
 Maternal PMTCT regimen i.e. HAART-exposed or HAART-unexposed  
 HAART initiation date (used to derive duration of HAART*) 
 HAART regimen*( first used in pregnancy) 
 Actual date of delivery (used to derive duration of HAART*) 
 HIV PCR status of infant –unknown, negative or positive 
Demographics: 
 maternal date of birth (to derive maternal age*) 
 race group* 
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Substance use: 
 illicit substance use (during pregnancy) 
 alcohol usage* (during pregnancy) 
 smoking* (during pregnancy) 
HIV Disease: 
 maternal WHO clinical stage* (during pregnancy) 
 lowest maternal CD4 cell count* (during pregnancy or up to 3 weeks post 
partum) 
Health Status: 
 hypertension* (systolic blood pressure [BP]>160mmHg or diastolic BP> 
90mmHg on 2 occasions 4 hours apart; or 1 diastolic BP> 110mmHg).  
 diabetes* (requiring intervention such as medication or delivery),  
 anaemia* (haemoglobin less than11gm/dl at any time during pregnancy),  
 severe anaemia* (haemoglobin less than 7gm/dl at any time during 
pregnancy) 
 syphilis* (positive RPR) 
 Tuberculosis (TB) (requiring medication ) 
o TB information only available for JH women 
 Reproductive Health: 
 gravidity (number of previous pregnancies) 
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 previous miscarriage 
 previous preterm birth  
Pregnancy and Infant outcomes 
 mode of delivery 
 infant gender 
 expected date of delivery (used to derive gestation*) 
 actual date of delivery (used to derive gestation*) 
 birth weight of infant  
 head circumference of infant 
 HIV PCR status of infant –unknown, negative or positive 
 
2.3.1 Explanation of key study variables 
Duration of HAART 
The duration of HAART was defined as the length of time on HAART from 
initiation of HAART to delivery. 
 
Gestational age 
Gestational age at birth was determined by comparing the expected and actual 
dates of delivery. Expected date of delivery was determined on the basis of early 
ultrasound biometry when available. When this was not available, last menstrual 
period of the mother or clinical measurement of fundal height was used.  
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Infants born at or after 37 weeks of gestation were classified as term. Infants 
born before 37 weeks of gestation were classified preterm and those born before 
34 weeks, as extremely premature. 
 
Birth weight 
Birth weights were obtained from maternal hospital files or information on the 
infant’s “Road-to-health card”. This is a patient-held health document of birth 
history, growth and immunizations issued to all infants born in South Africa at 
birth.  
 
Infants weighing 2.5kg or more at birth were classified as normal birth weight. 
Infants weighing less than 2.5kg at birth were classified as low birth weight (LBW) 
and those weighing less than 1.5kg were classified as very low birth weight 
(VLBW). Infants weighing less than 1.0 kg are defined as extremely low birth 
weight (ELBW) but this distinction was not made for the purposes of this study. 
 
Growth 
The weight and gestational age of each infant at birth were compared using an 
foetal-infantile growth chart [50] (appendix 1) to categorise infants into one of 3 
groups: 
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Small for gestational age (SGA) – those who fell below the 10th centile of 
expected weight for gestation age. 
Appropriate for gestational age (AGA) – those who fell on or between the 10th 
and 90th centiles of expected weight for gestational age. 
Large for gestational age (LGA) – those who fell above the 90th centile of 
expected weight for gestational age.  
 
2.4 STUDY DESIGN 
2.4.1 Study groups (for Phases 1 and 2): 
1) HAART-exposed vs. HAART-unexposed – The purpose of this 
comparison was to investigate the impact of HAART on birth outcomes. 
2) Early HAART-exposed vs. late HAART-exposed – The purpose of this 
comparison was to investigate the impact of the duration of HAART on 
birth outcomes. 
3) Early HAART: PI-based vs. NVP-based vs. EFV-based – The purpose of 
this comparison was to investigate the impact of regimen on birth 
outcomes (specifically in women who received a relatively long duration of 
HAART). 
4) Late HAART: PI-based vs. NVP-based vs. EFV-based – The purpose of 
this comparison was to investigate the impact of regimen on birth 
outcomes (specifically in women who received a relatively short duration 
of HAART).  
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5) RM HAART-exposed women vs. JH HAART-exposed women – The 
purpose of this comparison was to investigate for inherent differences in 
study hospitals in terms of birth outcomes and their risk factors. 
 
2.4.2 Study Phases 
Phase 1 
In order to contextualise each group and detect inherent differences which have 
been known to affect infant birth weight and gestation, study groups were 
compared in terms of demographics, substance abuse, HIV disease, health 
status and reproductive health [28, 48, 51, 52]. 
 
Phase 2 
Study groups were compared in terms of risk for specific pregnancy and infant 
outcomes. Pregnancy outcomes included duration of HAART and mode of 
delivery. The key Infant outcomes compared were infant weight and gestation. 
Other associated infant outcomes such as gender, weight for age, head 
circumference and HIV status were also analysed. 
 
Phase 3 
To control for the effect of infant HIV status on birth weight [48]. Infants with 
known HIV negative status were analysed to detect associations between study 
variables (see variables with * above) and LBW.  
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A further analysis of all infants was done to detect associations between study 
variables and preterm birth.  
 
Phase 4 
Variables associated with LBW or preterm birth in univariate analysis (P<0.1) 
were included in the multivariate model and retained if their removal markedly 
altered the model fit. Adjusted odds ratios were derived for HAART-exposed 
women for each of the variables using the HAART-unexposed women as a 
reference group.  
 
2.5 AUXILLIARY SERVICES 
2.5.1 Laboratory services 
These services were provided routinely by the NHLS (National Health and 
Laboratory Service). 
Laboratory tests 
HIV status was determined at first antenatal visit using 2 Rapid HIV tests – First 
Response HIV Card test 1-2.0 [Kachigam, Daman, India] and Pareekshak HIV 
Triline card test [Bangalore, Karnataka, India]. 
 
CD4 cell count was determined using a Beckman Coulter (Fullerton, CA) Epics 
XL MCL cytometer and Beckman Coulter TQ PREP. 
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HIV diagnosis was determined in infants aged 6 weeks or older with a DNA 
polymerase chain reaction (PCR) test (Amplicor HIV-1 DNA PCR version 1.5 
assay; Roche Diagnostics, Inc., Alameda, CA) by a locally validated protocol [47]. 
 
2.5.2 Data Analysis 
Although the author was involved in data interpretation, she was guided by an 
epidemiologist (Prof. Matthew Chersich). 
 
Initially univariate analysis was done, comparing the risk of study outcomes in 
different exposure groups.   Statistical tests were used to detect an association 
between exposure variables and study outcomes (chi-square test for categorical 
variables and Student’s t test for continuous exposure variables). The strength of 
associations detected was shown in odds ratios, with 95% confidence intervals 
used to demonstrate levels of uncertainty of these estimates. Conversely, when 
no association was detected, some margin of assurance could be provided that 
such exposures do not increase odds of preterm birth or low birth weight. The 
95% confidence intervals denote such margins of assurance.   
 
Bivariate analysis was also undertaken to compare differences in outcomes in 
population sub-groups. The duration that HAART was received was categorized, 
forming a binary variable (early and late HAART exposure). Thereafter an 
analysis of the effect of HAART exposure on pregnancy outcomes was assessed 
in each stratum of duration. This allowed for stratum-specific odds ratios to be 
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calculated, specifically the odds of LBW in women who received PI-based early 
HAART (The primary outcome of interest).  
 
Multivariate logistic regression analysis was done, using backward fitting to 
develop model which best characterizes the data. Variables were retained in the 
model if their removal markedly altered the model fit. Log-rank tests were used to 
build and evaluate results of the multivariate model.  
 
Multivariate analyses examined the risk factors for LBW in the group of women 
who were known to have had PCR negative infants and risk factors for preterm 
birth in all women. Variables chosen for this analysis included HAART-exposure 
according to regimen, CD4 category; maternal age and hypertension. The model 
analysed the odds of LBW according to regimen type: PI-based HAART, NVP-
based HAART and EFV-based HAART; each rise in CD4 category (in cells/mm3): 
0-49, 50-99, 100-149, 150-199 and 200-250; each year of increase in maternal 
age and for the presence or absence of maternal hypertension. 
 
Women exposed to early and late HAART were analysed separately because of 
interaction within the variable of HAART regimen for instance women exposed to 
early EFV-based HAART had a much higher odds ratio of LBW than those 
exposed to late EFV-based HAART.  
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Single Data entry was done in Microsoft Access.  Intercooled Stata 8.0 (Stata 
Corporation, College Station, TX, United states) was used for data analysis. 
 
Missing data 
Analysis of data was restricted to subjects with a complete data set on the 
specific variable involved. No imputation of data was performed. 
 
Student’s t-tests and chi-squared tests were performed to determine 
characteristics of women and children with incomplete information. Fisher’s exact 
test was utilized for analysis of categorical variables with sparse data and Wilcox 
sum rank test was performed when data was skewed.  We attempted to evaluate 
the influence of missing data by performing comparisons among women with and 
without information on HAART duration to make sure these did not differ 
significantly.  
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2.5.3 Funding 
The study did not require any external funding. The clinics where the study took 
place were funded by the South African Department of Health and are supported 
by the following NGOs:  ECHO (Enhancing Children’s HIV Outcomes), RHRU 
(Reproductive Health and HIV Research Unit), The Elizabeth Glaser Pediatric 
Aids Foundation and USAID’s (United State Agency International Development) 
PEPFAR (President’s Emergency Plan for AIDS Relief) programme. 
 
2.6 ETHICAL CONSIDERATIONS 
2.6.1 Patient Consent 
Each antenatal and postnatal clinic has a database of attendees to assist with 
statistical collection for the Department of Health and to monitor and evaluate 
clinic systems. At RM Hospital, patients were requested to sign a voluntary 
consent form allowing for use of anonymous data for study purposes (Appendix 
2). Patients who did not consent to this were excluded from the study. At JH 
Hospital women provided verbal consent for inclusion in the database 
 
2.6.2 Confidentiality 
Every effort was made to maintain patient confidentiality. The databases were 
analysed once patient names were removed. Only people directly involved in the 
study had access to the databases.  
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2.6.3 Ethics Approval 
The protocol was approved by the Human Research Ethics Committee of the 
University of the Witwatersrand on 07 May 2007. Ethics number: Protocol 
M070438; R14/49 van der Merwe   
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CHAPTER 3 
 
3.0 RESULTS 
 
3.1 STUDY POPULATION BREAKDOWN 
The study comprised 1630 women, 233 (14%) who were unexposed to HAART 
and 1397 (86%) who received HAART during their pregnancy. In the HAART-
exposed group, 49% (690) and 51% (707) of women accessed care at RM and 
JH hospitals respectively. All of the HAART-unexposed women were from RM. 
 
The HAART-exposed group comprised of 553 (40%) women who were known to 
have received HAART before 28 weeks of gestation (early HAART) and 427 
(30%) women known to have received HAART after 28 weeks of gestation (late 
HAART). The duration of HAART exposure during pregnancy was unknown for 
417 (30%) women.  
 
In the early HAART group, 157 (28%) women received PI-based HAART, 254 
(46%) received NVP-based HAART and 142 (26%) received EFV-based HAART. 
In the late HAART group, 290 (68%) women received PI-based HAART, 116 
(27%) received NVP-based HAART and 21 (5%) received EFV-based HAART.  
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Figure 3.1 Flow diagram of study population 
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3.2 DEMOGRAPHICS AND MATERNAL HEALTH STATUS  
(Tables 3.1.1, 3.1.2 and 3.1.3) 
3.2.1 Demographics 
Maternal Age 
The age of women in the study was available for 77% (180/233) of HAART-
unexposed and 98% (1372/1397) of HAART-exposed women. Mean age in the 
HAART-unexposed group was 28.9 (SD 5.1) which was lower than the HAART-
exposed group’s mean age of 30.3 (SD 5.1) (P<0.001). 
The majority of women were between 25 to 34 years of age (65%) with the 
remaining third of women were almost equally split between the age groups of 16 
to 24 years (17%) and 35 to 52 years (18%).  
 
Figure 3.2.1 Age distribution of study population according to HAART-exposure 
Age distribution of study population 
according to HAART-exposure
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Mean age of women exposed to HAART at RM and JH (30.2 [sd5.1] vs. 30.4 
[sd5.2],) as well as age between early and late HAART exposure (30.6 [sd5.1] vs. 
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30.1 [sd5.2]) did not differ (P= 0.53 and 0.18 respectively). Neither did the mean 
age of women exposed to different HAART regimens across the groups differ 
(P=0.23 for early HAART and P=0.49 for late HAART). 
 
Race Group 
Information on race was available for 16% (37/233) of the HAART-unexposed 
and 50% (694/1397) of the HAART-exposed group. The predominant race across 
all groups was black - 94% of HAART-unexposed and 98% of HAART-exposed 
women (P=0.15).  
 
The black race group was more common at JH than RM (99% vs. 92%, 
P<0.001). 
 
Women exposed to early HAART were more likely to be black than those 
exposed to late HAART (98% vs. 96%, P=0.016). No white or Indian women 
were exposed to early HAART versus three who received late HAART. Racial 
split did not differ according to regimen use.  
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Table 3.1.1 Demographics and maternal health status in women exposed and unexposed 
to antiretroviral treatment and by duration of exposure 
Variable 
category 
Variables 
HAART-
unexposed 
 
 (A) 
N=233 
HAART-
exposed  
 
(B) 
N=1397 
P value  
 
(A vs. B) 
 
Early 
HAART-
exposed  
(C) 
N=553 
Late 
HAART-
exposed 
 (D) 
N=427 
P value  
 
(C vs. D) 
 
D
e
m
o
g
ra
p
h
ic
s
  
 
Maternal age 
   mean years (SD) 
N=180 
28.9 (5.1) 
N=1372 
30.3 (5.1) 
 
<0.001 
N=540 
30.6 (5.1) 
N=426 
30.1 (5.2) 
 
0.18 
Race group n (%)  
   Black 
   mixed ancestry 
   Indian/White 
N=37 
34 (94) 
2 (6) 
0 (0) 
N=694 
680 (98) 
10 (1) 
4 (1) 
 
 
 
0.15 
N=341 
335 (98) 
6 (2) 
0 (0) 
N=125 
120 (96) 
2 (2) 
3 (2) 
 
 
 
0.016 
S
u
b
s
ta
n
c
e
 u
s
e
 
Smoked in pregnancy  
n (%) 
 
6 (4) 
 
28 (4) 
 
0.69 
 
15 (5) 
 
7 (2) 
 
0.085 
Alcohol use in pregnancy: 
n (%)    
 
7 (5) 
 
29 (4) 
 
0.51 
 
15 (5) 
 
7 (2) 
 
0.085 
H
IV
 d
is
e
a
s
e
 
WHO stage n (%) 
   stage 1  
   stage 2 
   stage 3  
   stage 4 
N=6 
3 (50) 
1 (17) 
1 (17) 
1 (17) 
N=744 
446 (60) 
94 (13) 
160 (22) 
44 (6) 
 
 
 
 
0.71 
N=256 
149 (58) 
33 (13) 
55 (21) 
19 (7) 
N=270 
180 (67) 
35 (13) 
43 (16) 
12 (4) 
 
 
 
 
0.13 
Immunological status  
CD4 cells/mm
3 
n (%)
   
                   
   0-49   
   50-99  
   100-149 
   150-199 
   200-250 
   mean CD4 cell count 
   SD 
   median CD4 cell count  
   IQR 
N=233 
 
5 (2) 
29 (12) 
35 (15) 
64 (27) 
100 (43) 
176.0  
55.9 
191 
136-220 
N=1397 
 
124 (9) 
216 (15) 
325 (23) 
412 (29) 
320 (23) 
146.1  
62.5 
154  
101-195 
 
 
 
 
 
 
<0.001 
 
 
 
<0.001 
N=553 
 
59 (11) 
91 (16) 
122 (22) 
156 (28) 
125 (23) 
141.8  
64.3 
152  
93-195  
N=427 
 
28 (7) 
62 (15) 
108 (25) 
136 (32) 
93 (22) 
149.9 
58.3 
155 
108-194 
 
 
 
 
 
 
0.12 
 
 
 
0.12 
H
e
a
lt
h
 s
ta
tu
s
 
Hypertension in 
pregnancy n (%) 
18 (12) 93 (10) 0.38 41 (10) 27 (8) 0.32 
Diabetes history n (%) 1 (1) 3 (0) 0.51 1 (0) 2 (1) 0.46 
Haemoglobin (Hb) 
Hb <11gm/dl, n (%) 
Median Hb gm/dl 
IQR 
N=100 
57 (57) 
10.7 
9.8-11.5 
N=912 
416 (46) 
11.1 
9.9 -11.9 
 
0.03 
 
0.019 
N=312 
129 (41) 
11.3  
10.1-12.1 
N=286 
140 (49) 
11.0 
9.9-11.8 
 
0.062 
 
0.007 
Syphilis serology n (%) 
positive RPR  
 
3 (2) 
 
35 (4) 
 
0.29 
 
11 (4%) 
 
11 (3) 
 
0.60 
R
e
p
ro
d
u
c
ti
v
e
 h
e
a
lt
h
 
Gravidity n (%) 
   1 
   2 
   3 
   ≥4 
   median 
   IQR 
N=204 
30 (15) 
83 (41) 
59 (29) 
32 (16) 
2 
2-3 
N=954 
126 (13) 
351 (37) 
292 (31) 
185 (19) 
2  
2-3 
 
 
 
 
0.50 
 
0.13 
    N=413 
51 (12)  
142 (34) 
131 (32) 
89 (22) 
3 
2-3 
N=354 
57 (16) 
140 (40) 
98 (28) 
59 (17) 
2  
2-3 
 
 
 
 
0.083 
 
0.010 
Previous miscarriage*:  
n (%)  
 
27 (18) 
 
130 (17) 
 
0.66 
 
70 (22) 
 
38 (12) 
 
0.001 
Previous preterm infant*  
n (%) 
 
16 (11) 
 
39 (6) 
 
0.055 
 
13 (6) 
 
18 (6) 
 
0.71 
All women have a CD4 ≤250cells/mm
3
; SD – standard deviation; IQR –interquartile range; RPR – rapid plasma reagin  
*in women with a previous pregnancy     
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Table 3.1.2 Comparison of demographics and maternal health status in women receiving different antiretroviral regimens in pregnancy 
Variable 
Category 
Variables 
Early HAART-exposed N=553 
 
P 
Late HAART-exposed N=427 
 
P 
PI-based 
HAART 
N=157 
NVP-based 
HAART 
N=254 
EFV-based 
HAART 
N=142 
PI-based 
HAART 
N=290 
NVP-based 
HAART 
N=116 
EFV-based 
HAART 
N=21 
 
Demograp
hics 
 
Maternal age mean years (SD); n 30.9 (4.8);156 30.2 (5.2);248 31.1 (5.1);136 0.23 30.0 (5.0);290 30.6 (5.6);115 29.5 (5.3);21 0.49 
Race group n (%)  
   Black 
   mixed ancestry 
   Indian/White 
N=33 
32 (97) 
1 (3) 
0 (0) 
N=199 
198 (99%) 
1 (1) 
0 (0) 
N=109 
101 (96) 
4 (4) 
0 (0) 
 
 
 
0.11 
N=35 
32 (91) 
1 (3) 
2 (6) 
N=82 
80 (98) 
1 (1) 
1 (1) 
N=8 
8 (100) 
0 (0) 
0 (0) 
 
 
 
0.57 
Substance 
use 
Smoked in pregnancy n (%) 4 (4) 9 (7) 2 (3) 0.39 3 (1) 4 (6) 0 (0) 0.085 
Alcohol in pregnancy: n (%)    3 (3) 9 (7) 3 (4) 0.38 1 (0) 6 (8) 0 (0) <0.001 
HIV 
disease 
WHO stage n (%) 
   stage 1  
   stage 2 
   stage 3  
   stage 4 
N=81 
63 (78) 
11 (14) 
6 (7) 
1 (1) 
N=109 
57 (52) 
17 (16) 
27 (25) 
8 (7) 
N=66 
29 (44) 
5 (8) 
22 (33) 
10 (15) 
 
 
 
 
<0.001 
N=186 
145 (78) 
25 (13) 
14 (8) 
2 (1) 
N=66 
32 (48) 
8 (12) 
18 (27) 
8 (12) 
N=18  
3 (17) 
2 (11) 
11 (61) 
2 (11) 
 
 
 
 
<0.001 
Immunological status cells/mm
3 
n (%) 
   0-50  
   50-100  
   100-150 
   150-200 
   200-250 
   median CD4 cell count  
   IQR 
N=157 
12 (8) 
25 (16) 
32 (20) 
42 (27) 
46 (29 
164.0  
103-203 
N=254 
26 (10) 
40 (16) 
55 (22) 
79 (31) 
54 (21) 
155.5  
97-193 
N=142  
21 (15) 
26 (18) 
35 (25) 
35 (25) 
25 (18) 
138.0  
76-188 
 
 
 
 
 
0.20 
 
0.034 
N=290 
19 (7) 
43 (15) 
75 (26) 
89 (31) 
64 (22) 
154.0  
107-196 
N=116 
5 (4) 
13 (11) 
29 (25) 
42 (36) 
27 (23) 
159.5  
130-196 
N=21 
4 (19) 
6 (29) 
4 (19) 
5 (24) 
2 (10) 
109.0  
74-164 
 
 
 
 
 
0.12 
 
0.012 
Health 
status 
Hypertension in pregnancy n (%) 8 (8) 23 (12) 10 (9) 0.59 12 (5) 15 (16) 0 (0) 0.003 
Diabetes history n (%) 1 (1) 0 (0) 0 (0) 0.22 1 (0) 1 (1) 0 (0) 0.76 
Haemoglobin (Hb) 
   Hb<11gm/dl, n (%) 
   median Hb gm/dl  
   IQR 
N=97 
38 (39) 
11.2  
10.1-11.9 
N=133 
58 (43) 
11.2  
10.2-12.2 
N=82  
33 (40) 
11.5  
9.5-12.4 
 
0.78 
 
0.63 
N=185 
88 (48) 
11.0  
9.9-11.7 
N=86 
42 (49) 
11.1  
10.0-11.8 
N=15 
10 (67) 
10.2  
8.6-12.0 
 
0.36 
 
0.38 
Syphilis serology n positive RPR (%) 5 (5) 4 (4) 2 (3) 0.84 8 (3) 3 (3) 0 (0) 0.78 
TB history n (%) 1 (10) 25 (14) 25 (28) 0.01 0 (0) 12 (15) 1 (17) 0.91 
Reproduct
ive health 
Gravidity n (%) 
   1 
   2 
   3 
   ≥4 
N=108 
15 (14) 
37 (34) 
37 (34) 
19 (18) 
N=196 
19 (10) 
71 (36) 
61 (31) 
45 (23) 
N=109 
17 (16) 
34 (31) 
33 (30) 
25 (23) 
 
 
 
 
0.66 
N=237 
43 (18) 
94 (40) 
63 (27) 
37 (16) 
N=100 
9 (9) 
40 (40) 
31 (31) 
20 (20) 
N=17 
5 (29) 
6 (35) 
4 (24) 
2 (12) 
 
 
 
 
0.29 
Previous miscarriage*: n (%)  22 (21) 36 (26) 12 (17) 0.34 23 (10) 11 (17) 4 (27) 0.059 
Previous preterm infant* n (%) 5 (5) 7 (8) 1 (2) 0.47 13 (6) 2 (5) 3 (23) 0.042 
All women have a CD4 ≤250cells/mm
3
; SD – standard deviation; IQR –interquartile range; RPR – rapid plasma reagin *in women with a previous pregnancy  
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Table 3.1.3 Demographics and maternal health status in women attending HAART clinic at Rahima 
Moosa (RH) and Charlotte Maxeke Johannesburg Academic Hospital (JH)  
Variable 
category 
Variables 
HAART-
unexposed 
(A) 
 
N=233  
HAART-
exposed  
RM (B) 
 
N=690 
HAART 
exposed  
JH (C) 
 
N=707 
P value 
  
(B vs. C) 
Demographics  
 
Maternal age  
   mean years (SD) 
N=180 
28.9 (5.1) 
N=681 
30.2 (5.1) 
N=691 
30.4 (5.2) 
 
0.53 
Race group n (%)  
   Black 
   mixed ancestry 
   Indian/White 
N=37 
34 (94) 
2 (6) 
0 (0) 
N=118 
108 (92) 
8 (7) 
2 (2) 
N=576 
572 (99) 
2 (0) 
2 (0) 
 
 
 
<0.001 
Substance use 
Smoked in pregnancy n /(%) 6 (4) 14 (3) 14 (4) 0.36 
Alcohol use in pregnancy: n (%)    7 (5) 8 (2) 21 (6) 0.001 
HIV disease 
WHO stage n (%) 
   stage 1  
   stage 2 
   stage 3  
   stage 4 
N=6 
3 (50) 
1 (17) 
1 (17) 
1 (17) 
N=385 
281 (73) 
46 (12) 
46 (12) 
12 (3) 
N=359 
165 (46) 
48 (13) 
114 (32) 
32 (9) 
 
 
 
 
<0.001 
Immunological status CD4 cells/mm
3
 
n (%) 
   0-50  
   50-100 
   100-150  
   150-200  
   200-250  
mean CD4 cell count (SD) 
N=233 
 
5 (2) 
29 (12) 
35 (15) 
64 (27) 
100 (43) 
176.0 (55.9) 
N=690 
 
55 (8) 
108 (16) 
158 (23) 
200 (29) 
169 (24) 
147.8 (62.3) 
N=707 
 
69 (10) 
108 (15) 
167 (24) 
212 (30) 
151 (21) 
144.4 (62.3) 
 
 
 
 
 
 
0.56 
0.31 
Health status 
Hypertension in pregnancy n (%) 18 (12) 33 (7) 60 (13) 0.005 
Diabetes history n (%) 1 (1) 3 (1) 0 (0) 0.08 
Haemoglobin (Hb) n (%) 
   Hb<11gm/dl 
   Hb<7gm/dl 
   median Hb (gm/dl)  
   IQR 
N=100 
57 (57) 
2 (2) 
10.7  
9.8-11.5 
N=427 
199 (47) 
7 (2) 
11.0 
9.9-11.8 
N=485 
217 (45) 
11 (2) 
11.2  
9.9-12.0 
 
0.57 
0.34 
 
0.16 
Syphilis serology n positive RPR (%) 3 (2) 19 (4) 16 (4) 0.89 
Reproductive 
health 
Gravidity n (%) 
   1 
   2 
   3 
   ≥4 
N=204 
30 (15) 
83 (41) 
59 (29) 
32 (16) 
N=467 
77 (16) 
179 (38) 
134 (29) 
77 (16) 
N=487 
49 (10) 
172 (35) 
158 (32) 
108 (22) 
 
 
 
 
0.004 
Previous miscarriage*: n (%)  27 (18) 63 (14) 67 (22) 0.002 
Previous preterm infant* n (%) 16 (11) 26 (6) 13 (8) 0.28 
All women have a CD4 ≤250cells/mm
3
; SD – standard deviation; IQR –interquartile range; RPR – rapid plasma reagin  
*in women with a previous pregnancy  
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3.2.2 Substance use 
Smoking 
Information on smoking during pregnancy was available for 60% (140/233) of HAART-
unexposed and 56% (777/1397) of HAART-exposed women. For both HAART-exposed and 
HAART-unexposed women, smoking rate was 4% (P=0.69). 
 
Similar rates of smoking were found in RM and JH women (3% vs. 4%, P=0.36).  
 
Women exposed to early and late HAART had similar rates of smoking (5% vs. 2%, 
P=0.085) as did women exposed to different HAART regimens. 
 
Alcohol and illicit substance use 
Information on alcohol or illicit substance use during pregnancy was available for 62% 
(140/233) of HAART-unexposed and 56% (782/1397) of HAART-exposed women. No 
women reported use of illicit substances. HAART-exposed and HAART-unexposed women 
had similar rates of alcohol use (4% vs. 5%, P=0.51). 
 
A higher rate of alcohol use was reported at JH than RM (6% vs. 2%, P=0.001). 
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Early and late HAART-exposed women reported similar rates of alcohol use (5% vs. 2%, 
P=0.085). In early HAART-exposed women, no regimen had a significant association with 
alcohol use (P=0.38). In late HAART-exposed women, NVP-based HAART was associated 
with a higher rate of alcohol use (8%) than PI-based (0%) and EFV-based (0%) regimens 
(P<0.001). 
 
3.2.3 HIV Disease 
WHO clinical stage 
WHO clinical stage of HIV was unavailable for the majority of HAART-unexposed women. In 
the HAART-exposed group, 53% (744/1397) of women had a documented WHO clinical 
stage. The majority of women, 60%, were WHO clinical stage 1 with 13%, 22% and 6% in 
WHO clinical stages 2, 3 and 4 respectively.   
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Figure 3.2.2 WHO clinical stages in HAART-exposed women 
HAART-exposed WHO Stage (%)
59%
13%
22%
6%
Stage 1
Stage 2
Stage 3
Stage 4
 
Among RM HAART-exposed women, a higher rate had WHO clinical stage 1 disease than 
among JH women (73% vs. 46%, P<0.001). JH women had a higher rate of stage 3 disease 
than RM women (32% vs. 12%, P<0.001).  
 
Women exposed to early and late HAART had similar rates of WHO clinical stages 1 through 
4. For both early and late HAART groups, PI-exposed women had a higher rate of stage 1 
disease than NVP-exposed and EFV-exposed women (P<0.001).  Among women exposed 
to late HAART, more EFV-exposed women were stage 3 disease compared to NVP-exposed 
and PI-exposed women (61% [11/18] vs. 27% [18/66] and 8% [14/186], P<0.001). 
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Figure 3.2.3 WHO clinical stages for late HAART exposure according to regimen 
 
WHO stages (%)for late PI-exposure
78%
13%
8%
1%
Stage 1
Stage 2
Stage 3
Stage 4
 
 WHO stages (%) for late NVP-exposure
49%
12%
27%
12%
 
 WHO stage (%) for late EFV-exposure
17%
11%
61%
11%
 
Immunological status 
The immunological status in the form of a CD4 cell count was known for all women included 
in the study. The median CD4 cell count for the HAART-unexposed women was higher than 
that of HAART-exposed (191cells/mm3 [IQR136-220] vs.154cells/mm3 [IQR101-195], 
P<0.001).  
 
Mean CD4 cell count of was similar between RM and JH women (147.8cells/mm3 vs. 
144.4cells/mm3, P=0.31) and women exposed to early HAART had a similar mean CD4 cell 
count to those exposed to late HAART (141.8cells/mm3 vs. 149.9cells/mm3, P=0.12). 
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Among the early HAART group, EFV-exposed women had the lowest median CD4 cell count, 
followed by NVP-exposed and then PI-exposed women (138cells/mm3vs. 155.5cells/mm3 vs. 
164cells/mm3, P=0.034). Among the late HAART group, EFV-exposed women had the lowest 
median CD4 cell count, followed by PI-exposed and then NVP-exposed women 
(109cells/mm3 vs..154cells/mm3 vs. 159cells/mm3, P=0.012). Median CD4 cell counts for PI-
exposed and NVP-exposed women were similar (P=0.35). 
 
3.2.4 Health status 
Hypertension 
Information on the presence of hypertension requiring medication was available for 62% 
(145/233) of HAART-unexposed and 66% (929/1397) of HAART-exposed women. 
Hypertension was present in 12% of HAART-unexposed and 10 % of HAART-exposed 
women (P=0.38).  
 
More JH than RM HAART-exposed women were hypertensive (13% vs. 7% P= 0.005).  
 
Similar rates of hypertension were found in early and late HAART-exposed women (10% vs. 
8%, P=0.32). For early HAART-exposed women, no regimen was associated with 
significantly higher rates of hypertension. For Late HAART-exposed women, NVP-based 
HAART was associated with a higher rate of hypertension than PI or EFV-based HAART 
(16% vs. 5% and 0%, P=0.003). 
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Diabetes 
Information on diabetes requiring medication was available for 63% (147/233) of HAART-
unexposed and 67% (932/1397) of HAART-exposed women. Few women were identified as 
being diabetic – one HAART-unexposed and three HAART-exposed women and all these 
were from RM hospital. 
 
 Of HAART-exposed diabetics, one started HAART early (on PI-based HAART) and two 
started HAART late (one on PI-based and one on NVP-based HAART). 
 
Anaemia 
Anaemia was defined as haemoglobin less than 11gm/dl. Haemoglobin value during 
pregnancy was available for 43% (100/233) of HAART-unexposed and 65% (912/1397) of 
HAART-exposed women. High rates of anaemia were found in all groups with 57% of 
HAART-unexposed and 46% of HAART-exposed women having haemoglobin values of less 
than 11gm/dl (P=0.03) and 2% of women in both groups having haemoglobin values of less 
than 7gm/dl. Mean haemoglobin values for HAART-unexposed and exposed women were 
10.6gm/dl (SD 1.5) and 10.9gm/dl (SD 1.6) respectively (P=0.06) 
 
The rates of anaemia for RM and JH women were similar (47% vs.45%, P=0.57).  
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Of women exposed to early and late HAART, 41% and 49% were anaemic respectively 
(P=0.062). Rates of anaemia did not differ across the different regimens in the early (P=0.78) 
and late (P=0.36) groups. 
 
Syphilis 
Syphilis serology (Rapid Plasma Reagin [RPR]) results were available for 59% (137/233) of 
HAART-unexposed and 62% (864/1397) of HAART-exposed women. Among HAART-
unexposed and HAART-exposed groups, 3 (2%) and 35 (4%) were found to be RPR positive 
respectively (P=0.29).  
  
Positive RPR rates were similar in RM and JH women (both 4% [P=0.89] as well as women 
exposed to early and late HAART (4% vs. 3%, P=0.60) and across all treatment regimens. 
 
Tuberculosis 
Information on tuberculosis (TB) was only available for HAART-exposed JH women and 
among these only 33% (466/1397) had documented TB information. Of these women, 17% 
(80/466) had a history of TB. 
 
Among the early HAART group, EFV-exposed women had a higher rate of positive TB 
history than NVP-exposed or PI-exposed women (28% [25/88] vs. 14% [25/183] and 10% 
[1/10], P=0.01). In the late HAART group, 0% (0/1), 15% (12/78) and 17% (1/6) of women 
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exposed to PI-based, NVP-based and EFV-based HAART respectively had a history of TB 
(P=0.91). 
 
3.2.5 Reproductive Health 
Gravidity 
Information on gravidity was available for 88% (204/233) of HAART-unexposed and 68% 
(954/1397) of HAART-exposed women. These groups did not differ  in terms of gravidity with 
the majority of women on their second or third pregnancy – 41% and 29% of HAART-
unexposed and 37% and 31%  of HAART-exposed respectively (P=0.50). Only 15% of 
HAART-unexposed and 13% of HAART-exposed women were primigravida. Both HAART-
unexposed and HAART-exposed women had a median gravidity of 2 (IQR 2-3) (P=0.13).  
 
HAART-exposed women at RM had a more primigravida women than JH (16% vs. 10%) and 
fewer women with a gravidity of 4 or more than JH (16% vs. 22%, P=0.004). 
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Figure 3.2.4 Breakdown of gravidity according to HAART-exposure and hospital 
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Among the HAART-exposed group, for both early and late HAART, most women were on 
their second or third pregnancies. Women exposed to early HAART were more likely to be on 
their third pregnancy (median gravidity of 3) versus women exposed to late HAART who 
were more likely to be on their second pregnancy (median gravidity of 2) (P=0.01). Only 12% 
and 16% of women were primigravida in the early and late HAART-exposed groups 
respectively. 
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Figure 3.2.5 Breakdown of gravidity according to HAART duration 
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The breakdown for gravidity within early and late HAART groups according to regimens did 
not differ significantly (see table 3.1.2). 
 
Previous miscarriage 
Previous miscarriage rate was assessed for all women with a previous pregnancy. The rates 
of previous miscarriage were available for 84% (146/174) of HAART-unexposed and 93% 
(766/828) of HAART-exposed women and these did not differ significantly (18% vs. 17%, 
P=0.66).  
 
There were more previous miscarriages in the JH HAART-exposed group (22%) compared to 
the RM HAART-exposed group (14%) (P=0.002).  
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Previous miscarriages were more common in women exposed to early HAART than late 
HAART (22% vs.12%, P=0.001). Rates of previous miscarriages were similar for all regimen 
groups.  
 
Previous preterm birth 
Previous preterm birth rate was assessed for all women with a previous pregnancy. This was 
available for 85% (148/174) of HAART-unexposed and 75% (621/828) of HAART-exposed 
women who were known to have had a previous pregnancy. HAART-unexposed and 
HAART-exposed women had a previous preterm birth rate of 11% and 6% respectively 
(P=0.055).  
 
RM and JH HAART-exposed women had similar previous preterm birth rates of 6% and 8% 
respectively (P=0.28).  
 
Both early and late HAART women had previous preterm rates of 6% (P=0.71). Women 
exposed to early HAART had similar previous preterm rates across all regimen types. 
Women exposed to EFV-based late HAART had higher previous preterm rates than those 
exposed to PI-based or NVP-based late HAART (23% vs. 6% or 5%, P=0.042). 
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Summary: demographics and maternal health status  
Table 3.1.4 Summary of demographic and maternal health status variables 
Variables showing no difference across groups marked with X 
Variables showing a difference are marked with D 
 
Variable 
HAART-
exposed 
vs. HAART-
unexposed 
Early 
HAART vs. 
late 
HAART 
RM vs. JH 
PI vs. NVP. 
vs. EFV in 
early HAART 
PI vs. NVP 
vs. EFV in 
late HAART 
Age D X X X X 
Race X D D X X 
Smoking X X X X X 
Alcohol X X D X D 
WHO stage X X D D D 
CD4 cell count 
group D X X X X 
CD4 cell count 
median D X X D D 
Hypertension X X D X D 
Diabetes X X D X X 
Anaemia D X X X X 
Syphilis X X X X X 
Gravidity X X D X X 
Previous 
miscarriage X D D X X 
Previous 
preterm X X X X D 
HAART-highly active antiretroviral therapy; RM – Rahima Moosa Mother and Child Hospital; JH – Charlotte Maxeke Johannesburg 
Academic Hospital; PI- protease inhibitor (exposure); NVP – nevirapine (exposure); EFV –efavirenz (exposure) 
 
Most women in the study were black, aged between 25 and 34 and experiencing their 
second or third pregnancy. HAART exposed women were older, had lower CD4 cell counts, 
and higher haemoglobin values than HAART-unexposed women. Women exposed to early 
HAART had more previous miscarriages than those exposed to late HAART. JH women had 
higher gravidity, more advanced HIV WHO clinical stage, increased alcohol use, increased 
likelihood of hypertension and more previous miscarriages than RM women. Women 
exposed to EFV-based HAART had the lowest median CD4 cell counts, the most clinically 
advanced HIV and were more likely to have a history of TB. Women exposed to late NVP-
based HAART had higher alcohol use than those exposed to other regimens. 
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3.3 PERINATAL CHARACTERISTICS AND INFANT OUTCOMES  
3.3.1 Perinatal Characteristics 
Pregnancy planning 
Among the HAART-unexposed and exposed women, 52 (22%) and 321 (23%) were asked 
whether the current pregnancy was planned. More than two thirds of women in both groups 
had not planned the pregnancy – 71% (37/52) and 72% (232/321) in the two groups 
respectively.  
 
Women exposed to early HAART had a lower rate of unplanned pregnancies than those 
exposed to late HAART but this was not significant (69% [97/141] vs. 79% [89/113], 
P=0.075). 
 
Time to HAART initiation from first Antenatal visit 
The amount of weeks from the first Antenatal visit to HAART initiation was available for 65% 
(903/1397) of HAART-exposed women. This was longest for EFV-based regimens followed 
by NVP-based and PI-based regimens (8.6 weeks [IQR4.3-17.9] vs. 5.2 weeks [IQR3.0-10.7] 
and 4.6 weeks [IQR2.3-8.0]). 
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Table 3.2.1 Perinatal characteristics and infant outcomes in women exposed and unexposed to antiretroviral treatment, and by duration 
of exposure 
Variable 
category 
Variables 
HAART-
unexposed  
(A) 
N=233  
HAART-
exposed 
(B) 
N=1397  
P value  
 
(A vs. B) 
Early HAART-
exposed 
(C) 
N=533 
Late HAART-
exposed  
(D) 
N=427 
P value  
 
(C vs. D) 
Pregnancy 
and 
Delivery 
Time taking HAART until delivery 
   median weeks  
   IQR    
 N=921 
9.7 
5.0-17.6 
 N=412 
18.4  
12.1-42.6 
N=416 
5.8  
3.3-8.5 
 
 
<0.001 
Mode of delivery n (%) 
   vaginal birth 
   c/s emergency 
   c/s elective 
N=188 
138 (73) 
36 (19) 
14 (7) 
N=1026 
734 (72) 
179 (17) 
113 (11) 
 
 
 
0.32 
N=412 
295 (72) 
68 (17) 
49 (12) 
N=410 
296 (72) 
69 (17) 
45 (11) 
 
 
 
0.92 
Infant 
Outcomes 
Infant gender n (%)        
   female  
N=227 
111 (49) 
N=994 
496 (50) 
 
0.79 
N=412 
210 (51) 
N=409 
205 (50) 
 
0.81 
Gestation n (%) 
   extremely premature  
   preterm 
   term/postdates 
N=147 
6 (4) 
1 (1) 
140 (95) 
N=946 
58 (6) 
80 (8) 
808 (85) 
 
 
 
0.002 
N=389 
40 (10) 
41 (11) 
308 (79) 
N=427 
3 (1) 
18 (4) 
406 (95) 
 
 
 
<0.001 
Birth weight (kg) n (%) 
   mean (SD)  
    0.75-1.49 
    1.5-2.49  
    >2.5 
N=224 
2.8 (0.6) 
10 (4) 
50 (22) 
164 (73) 
N=1004 
2.9 (0.6) 
16 (2) 
199 (20) 
789 (79) 
 
0.008 
 
 
      0.015 
N=388 
2.9 (0.6) 
8 (2) 
82 (21) 
298 (77) 
N=407 
2.9 (0.5) 
2 (0) 
74 (18) 
331 (81) 
 
0.39 
 
 
          0.071 
Birth weight – gestation n (%) 
   AGA 
   SGA 
   LGA 
N=138 
77 (56) 
59 (43) 
2 (1) 
N=792 
541 (68) 
214 (27) 
37 (5) 
 
 
 
<0.001 
N=312 
232 (74) 
57 (18) 
23 (7) 
N=400 
245 (61) 
147 (37) 
8 (2) 
 
 
 
<0.001 
Infant head circumference (cm)  
   mean (SD) 
N=138 
33.7 (2.5) 
N=801 
34.1 (2.2) 
 
0.034 
N=312 
34.0 (2.4) 
N=332 
34.3 (2.1) 
. 
0.20 
Infant HIV status n (%) 
   HIV PCR positive 
N=191 
37 (19) 
N=828 
45 (5) 
 
<0.001 
N=350 
8 (2) 
N=316 
31 (10) 
 
<0.001 
IQR – interquartile range; PI- protease inhibitor, NVP – nevirapine; EFV – efavirenz; C/s – caesarean section; SD – standard deviation; AGA – appropriate for gestational age; SGA – 
small for gestational age; LGA – large for gestational age; PCR –polymerase chain reaction 
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Table 3.2.2 Perinatal characteristics and infant outcomes in women receiving different antiretroviral regimens in pregnancy 
Variable 
category 
Variables 
Early HAART-exposed 
P 
Late HAART-exposed 
P 
PI-based 
HAART 
NVP-based 
HAART 
EFV-based 
HAART 
PI-based 
HAART 
NVP-based 
HAART 
EFV-based 
HAART 
Pregnancy 
and 
Delivery 
Time taking HAART until delivery 
   median weeks  
   IQR    
N=139 
17.1 
13.7-23.1 
N=192 
15.6 
10.7-25.8 
N=81 
62.7 
33.1-86.4 
 
 
<0.001 
N=290 
6.1 
3.3-8.7 
N=107 
5.1 
3.0-7.8 
N=19 
5.2 
3.9-9.4 
 
 
0.38 
Mode of delivery: n (%) 
   vaginal birth 
   c/s emergency 
   c/s elective 
N=135 
108 (80) 
19 (14) 
8 (6) 
N=181 
123 (68) 
27 (15) 
31 (17) 
N=96 
64 (67) 
22 (23) 
10 (10) 
 
 
 
0.009 
N=278 
220 (79) 
38 (14) 
20 (7) 
N=113 
65 (58) 
26 (23) 
22 (19) 
N=19 
11 (58) 
5 (26) 
3 (16) 
 
 
 
<0.001 
Infant 
Outcomes 
Infant gender: n (%) 
   female  
N=134 
64 (48) 
N=179 
95 (53) 
N=99 
51 (52) 
 
0.64 
N=280 
138 (49) 
N=109 
55 (50) 
N=20 
12 (60) 
 
0.65 
Gestation: n (%) 
   extremely premature  
   preterm 
   term/postdates 
N=131 
13 (10) 
6 (5) 
112 (86) 
N=167 
15 (9) 
25 (15) 
127 (76) 
N=91 
12 (13) 
10 (11) 
69 (76) 
 
 
 
  0.048 
N=290 
0 (0) 
9 (3) 
281 (97) 
N=116 
3 (3) 
8 (7) 
105 (91) 
N=21 
0 (0) 
1 (5) 
20 (95) 
 
 
 
0.024 
Birth weight (kg): n (%) 
   mean (SD)  
   0.75-1.49 
   1.5-2.49  
   >2.5 
N=135 
3.0 (0.6) 
5 (4) 
18 (13) 
112 (83) 
N=158 
2.9 (0.5) 
0 (0) 
31 (20) 
127 (80) 
N=95 
2.7 (0.6) 
3 (3) 
33 (35) 
59 (62) 
 
0.002 
 
 
<0.001 
N=284 
2.9 (0.5) 
2 (1) 
46 (16) 
236 (83) 
N=103 
2.9 (0.5) 
0 (0) 
23 (22) 
80 (78) 
N=20 
2.8 (0.5) 
0 (0) 
5 (25) 
15 (75) 
 
0.59 
 
 
0.50 
Birth weight – gestation n (%) 
   AGA 
   SGA 
   LGA 
N=123 
83 (67) 
26 (21) 
14 (11) 
N=128 
110 (86) 
13 (10) 
5 (4) 
N=61 
39 (64) 
18 (30) 
4 (7) 
 
 
 
0.001 
N=280 
153 (55) 
121 (43) 
6 (2) 
N=101 
79 (78) 
20 (20) 
2 (2) 
N=19 
13 (61) 
6 (32) 
0 (0) 
 
 
 
0.001 
Infant head circumference (cm): 
   mean (SD) 
N=91 
33.9 (2.4) 
N=141 
34.5 (2.6) 
N=80 
33.5 (1.9) 
 
0.006 
N=218 
34.1 (2.0) 
N=98 
34.6 (2.3) 
N=16 
33.8 (2.0) 
 
0.10 
Infant HIV status: n (%) 
   HIV PCR positive   
N=106 
1 (1) 
N=156 
6 (4) 
N=88 
1 (1) 
 
0.22 
N=214 
17 (8) 
N=87 
13 (15) 
N=15 
1 (7) 
 
0.17 
IQR – interquartile range; PI- protease inhibitor, NVP – nevirapine; EFV – efavirenz; C/s – caesarean section; SD – standard deviation;  
AGA – appropriate for gestational age; SGA – small for gestational age; LGA – large for gestational age; PCR –polymerase chain reaction 
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Table 3.2.3 Perinatal characteristics and infant outcomes in women attending HAART clinics at Rahima 
Moosa (RM) and Charlotte Maxeke Johannesburg Academic Hospital (JH) 
Variable 
Category 
Variable RM JH P 
value 
HAART 
HAART duration in pregnancy 
(median weeks) 
   early HAART (median weeks) 
   IQR 
   late HAART (median weeks) 
   IQR 
 
 
17.9  
14.7-26.6 
6  
3.2-8.7 
 
 
18.9  
10.9-58.1 
5.1  
3.1-7.9 
 
 
 
0.58 
 
0.24 
HAART Regimen n (%) 
   PI-based 
   NVP-based 
   EFV-based 
N=690 
589 (85) 
55 (8) 
46 (7) 
N=707 
21 (3) 
525 (74) 
161 (23) 
 
 
 
<0.001 
Delivery 
Mode of delivery n (%) 
   vaginal birth 
   c/s emergency 
   c/s elective 
N=565 
431 (76) 
93 (16) 
41 (7) 
N=461 
303 (66) 
86 (19) 
72 (16) 
 
 
 
<0.001 
Infant  
Outcomes 
Infant gender n (%)        
   female  
 
272 (49) 
 
224 (51) 
 
0.38 
Gestation n (%) 
   extremely premature  
   preterm 
   term/postdates 
N=553 
19 (3) 
28 (5) 
506 (92) 
N=393 
39 (10) 
52 (13) 
302 (77) 
 
 
 
<0.001 
Birth weight (kg) n (%) 
   mean (SD)  
   0.75-1.49 
   1.5-2.49  
   >2.5 
N=571 
2.9 (0.6) 
12 (2) 
109 (19) 
451 (79) 
N=432  
2.9 (0.6) 
4 (1) 
90 (21) 
338 (78) 
 
 
 
 
0.28 
Birth weight – gestation n (%) 
   AGA 
   SGA 
   LGA 
N=505 
292 (58) 
187 (37) 
26 (5) 
N=287 
249 (87) 
27 (9) 
11 (4) 
 
 
 
<0.001 
Infant head circumference (cm):  
   mean (SD) 
   median  
   IQR 
 
33.9 (2.1) 
34  
33-35 
 
34.3 (2.2) 
34  
33-35 
 
 
 
0.014 
Infant HIV status: n (%) 
   HIV PCR positive 
 
25 (6) 
 
20 (5) 
 
0.66 
early HAART – HAART initiated before 28 weeks of pregnancy; late HAART – HAART initiated at or after 28 weeks of pregnancy; IQR – 
interquartile range; PI- protease inhibitor, NVP – nevirapine; EFV – efavirenz; c/s – caesarean section; SD – standard deviation;  
AGA – appropriate for gestational age; SGA – small for gestational age; LGA – large for gestational age; PCR –polymerase chain reaction
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Duration of HAART  
(See tables 3.2.1, 3.2.2 and 3.2.3) 
Duration of HAART from initiation to delivery was available for 66% (921/1397) of women 
exposed to HAART. The median weeks on HAART for women who received early and late 
HAART was 5.8 weeks (IQR3.3-8.5) and 18.4 weeks (IQR12.1-42.6) respectively (P<0.001). 
  
Women from RM and JH had similar median durations of early HAART (17.9 vs. 18.9 weeks, 
P=0.58) and late HAART (6.0 vs. 5.1 weeks, P=0.24).  
  
Among the early HAART-exposed group, the median weeks on HAART was longer for EFV-
exposed than PI-exposed or NVP-exposed women (62.7 [IQR33.1-86.4] vs. 17.1 [IQR13.7-
23.1] and 15.6 [IQR10.7-25.8], P<0.001). 
 
Among the late HAART-exposed group, the median weeks on HAART was similar for PI-
based, NVP-based and EFV-based regimens (6.1 [IQR3.3-8.7] vs. 5.1 [IQR3.0-7.8] vs. 5.2 
[IQR3.9-9.4], P=0.38). 
 
Site of delivery – Regimen preference for study hospitals 
At RM hospital, the main regimen used was PI-based - 85% (589/690) of all HAART, 77% 
(145/188) of early and 90% (288/321) of late HAART.  At JH hospital the main regimen used 
was NVP-based - 74% (525/707) of all HAART, 64% (234/365) of early and 92% (97/106) of 
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late HAART. More JH women used EFV-based HAART than RM (23% vs.7%, P<0.001) 
particularly in the early HAART-exposed women. 
 
Figure 3.3.1 Regimens per hospital 
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Mode of delivery 
Mode of delivery was known for 81% (188/233) of HAART-unexposed and 73% (1026/1397) 
of HAART-exposed women. Vaginal birth occurred most commonly among both HAART-
unexposed and HAART-exposed (72% [734/1026] vs. 73% [138/188], P=0.32). Women 
exposed to early and late HAART were equally likely to have a vaginal birth (72% [295/412] 
vs. 72% [296/410], P=0.92).  
 
Of women exposed to early HAART, PI-exposed women had more vaginal births than those 
with NVP and EFV-exposure (80% [108/135]) vs. 68% [123/181] and 67% [64/96], P=0.009). 
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Of women exposed to late HAART, PI-exposed women also had more vaginal births than 
their NVP-exposed and EFV-exposed counterparts (79% [220/278] vs. 58% [65/113] vs. 58% 
[11/19], P<0.001). 
 
3.3.2 Infant Outcomes 
Infant gender 
Infant gender was recorded for 97% (227/233) of HAART-unexposed and 71% (994/1397) of 
HAART-exposed infants. Roughly half of all infants were female – 49% of HAART-
unexposed, 50% of HAART-exposed, 51% of early HAART-exposed, and 50% of late 
HAART-exposed. The male/female split was not different across the three regimen groups. 
 
Gestation 
Gestation at birth was known for 63% (147/233) of HAART-unexposed and 68% (946/1397) 
of HAART-exposed infants.  
 
Preterm birth rates were higher in HAART-exposed infants than HAART-unexposed infants 
(15% [138/946] vs. 5% [7/147], P=0.002). More infants exposed to early HAART were born 
preterm than those with late HAART exposure (21% [81/389] vs. 5% [21/427], P<0.001).  
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Figure 3.3.2 Gestation at birth according to HAART exposure and duration 
0% 50% 100%
Percentage of infants
HAART-
unexposed
HAART-
exposed
early
HAART
late HAART
Gestation at birth according to HAART 
exposure and duration
Extremely Preterm
Preterm
Term or Postdates
 
 
Among early HAART-exposed infants, NVP and EFV-exposure were linked to higher rates of 
preterm births than PI-exposure (24% [40/167] and 24% [22/91] vs. 15% [19/131], P=0.048).  
 
Among late HAART-exposed infants, preterm birth rates were highest for NVP-based 
followed by EFV-based and then PI-based regimens (9% [11/116] vs. 5% [1/21] vs. 3% 
[9/290], P=0.024).  
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Figure 3.3.3 Gestation at birth according to HAART regimen and duration 
0% 50% 100%
Percentage of infants
early PI
early NVP
early EFV
late PI
late NVP
late EFV
Gestation at birth according to HAART 
regimen and duration
Extremely Preterm
Preterm
Term or Postdates
 
Similar rates of extremely premature infants were born to HAART-unexposed and HAART-
exposed women (4% [6/147] vs. 6% [58/946], P=0.97). More early HAART-exposed than late 
HAART-exposed infants were extremely premature (10% [40/389] vs. 1% [3/427], P<0.001).  
 
Among early HAART-exposed infants the rate of extremely premature infants was similar for 
PI-based, NVP-based and EFV-based regimens (10% [13/131] vs. 9% [15/167] vs. 13% 
[12/91], P=0.56). In the late HAART-exposed group, three infants were born extremely 
premature after exposure to NVP-based regimens and none were born extremely premature 
after PI or EFV exposure (3% [3/116] vs. 0% [0/290] vs. 0% [0/21], P=0.017).  
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Birth Weight 
Low birth weight 
Birth weight was known for 96% (224/233) of HAART-unexposed and 72% (1003/1397) of 
HAART-exposed infants. The mean birth weight for the cohort was 2.88kg, with just less than 
a quarter of infants LBW (22.4% [275/1228]). Among infants with known HIV status, HIV-
positive infants had a higher rate of LBW than HIV negative infants (33% [24/73] vs. 22% 
[173/804], P=0.04). 
 
The mean birth weight for HAART-unexposed infants was 0.1kg less than those exposed to 
HAART (2.8kg [SD 0.6] vs. 2.9kg [SD 0.6], P=0.008). Similarly, more HAART-unexposed 
infants, were low birth weight (LBW) compared to HAART-exposed infants (27% [60/224] vs. 
21% [215/1003], P=0.081).  Among the HAART-exposed group, a similar rate of LBW was 
found in early HAART-exposed infants versus late HAART-exposed infants (23% [90/388] vs. 
19% [76/407], P=0.12).  
 
  77 
Figure 3.3.4 Weight at birth according to HAART exposure and duration 
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Among early HAART-exposure, women on EFV-based regimens had the highest rate of LBW 
followed by NVP-based and then PI-based regimens (38% [36/95] 20% [31/158] 17% 
[23/135], P<0.001). Among late HAART-exposure, women on EFV based regimens had the 
highest rate of LBW followed by NVP-based and then PI-based regimen (25% [5/20] vs. 22% 
[23/103] vs.17% [48/284], P=0.36).  
Birth weight   
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Figure 3.3.5 Weight at birth according to HAART regimen and duration 
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Very low birth weight 
Overall, only 26 (2%) infants were very low birth weight (VLBW). Table 3.3.1 summarises the 
maternal and infant characteristics of the 26 VLBW infants.  
Birth weight   
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Table 3.3.1: Maternal and infant characteristics of very low birth weight infants. 
 
CD4 
 
Site 
WHO 
stage Gravidity Known risk factors PMTCT 
Weeks on 
HAART  
Infant 
gender 
Mode of 
delivery 
Birth 
weight 
(kg) 
Gestation 
(weeks) 
weight 
vs. 
gestati
on 
Infant 
PCR 
result 
 
Age 
18 39 RM   3 PP PI HAART 3 Male em. c/s 1.48 30 AGA Negative 
51 31 JH       NVPHAART unknown   NVD 1.21 27 AGA   
51 33 RM   3 Hypertension PI HAART 11 Male NVD 0.65 30 SGA   
51 31 RM 1 2   PI HAART 19 Male NVD 1.45 35 SGA Negative 
57 34 JH 1 4   EFV HAART unknown Male em. c/s 1.40       
96 38 RM 2 2 Hypertension PI HAART 3 Male NVD 1.26 29 AGA Negative 
99 36 RM   3   No HAART   Male NVD 1.40 35 SGA Negative 
100 32 RM       PI HAART 73 Female NVD 1.10 27 AGA Negative 
110 27 RM 1 2 PMc PI HAART 1 Female NVD 1.02 27 AGA Negative 
111 19 RM   1   No HAART   Male em. c/s 1.10 28 AGA Negative 
128 27 RM 1 1   PI HAART 13 Male NVD 1.42       
136 35 RM   3 PMc, PP No HAART   Male NVD 1.03 30 AGA   
149 32 JH 1 3   EFV HAART 145 Female NVD 1.40 30 AGA   
149  RM   3   No HAART   Female em. c/s 1.20     Negative 
166 23 RM 1     PI HAART unknown Male em. c/s 1.00 29 AGA Negative 
176  RM   2   No HAART   Male NVD 1.39     Negative 
189 35 RM       PI HAART unknown Female   1.43     Positive 
200 27 RM   2 PMc, Alcohol, Smoking No HAART   Female em. c/s 1.10 27 AGA Negative 
208 31 RM   4   No HAART   Female em. c/s 1.34 29 AGA Negative 
209 29 RM 3 1 Chorioamnionitis PI HAART unknown   NVD 1.25       
211  RM   2   No HAART   Male NVD 1.27     Negative 
220 31 RM 1     PI HAART 14 Female NVD 1.24 31 AGA   
226 37 JH 1 4   EFV HAART unknown  Female em. c/s 1.02 28 AGA Negative 
239 24 RM       No HAART   Female   1.46     Negative 
239 24 RM       No HAART   Female   1.26     Negative 
248 32 RM   2   PI HAART 10 Male NVD 1.30 32     
 
JH, Charlotte Maxeke Johannesburg Academic Hospital; RM, Rahima Moosa Mother and Child Hospital; PP, Previous preterm delivery,; PMc, Previous 
miscarriage; PI HAART, Protease inhibitor based antiretroviral regimen; EFV HAART, efavirenz based antiretroviral regimen; NVP HAART, nevirapine based 
antiretroviral regimen; No HAART, no HAART - single dose of nevirapine to mother and/or infant or PMTCT missed; em.c/s, emergency caesarean section; NVD, 
normal vaginal delivery; AGA’ Appropriate for gestational age; SGA’ small for gestational age; PCR, polymerase chain reaction test for HIV.  
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The 26 VLBW infants had mothers aged between 19 and 39. Six women were 35 years or 
older. The mean maternal age of 30.7 years was not different to that of the rest of the cohort 
(30.0 years, P=0.05). Most VLBW pregnancies were managed at RM hospital (22/26) and 
more than a third of the women had a gravidity of 3 or more. CD4 cell counts of the mothers 
with VLBW infants ranged from 18 to 248cells/ mm3. The mean CD4 cell count of the VLBW 
group did not differ from the rest of the women (147.6cells/mm3 vs. 153.1cells/mm3, P=0.65). 
Of the 26 infants, only seven (27%) had known risk factors for LBW, three of the women had 
a previous miscarriage, two had a previous preterm delivery and two where hypertensive. 
Two women had multiple risk factors for preterm birth.  
 
More HAART-unexposed than HAART-exposed infants were VLBW (4% [10/224] vs. 2% 
[16/1004], P=0.01). Among the HAART-exposed women, eight early HAART-exposed and 
two late HAART-exposed infants were VLBW (2% [8/388] vs. 0% [2/407], P=0.05). The 
duration of HAART exposure varied considerably – between 1 and 145 weeks. Most of the 
HAART use was PI-based (80% [12/15]) but when early and late HAART were analysed 
separately, the rates of VLBW infants were similar for all regimens (P=0.58 and P=0.65 for 
early and late respectively). 
 
The number of male and females in the group were almost equal (13 vs. 11). More than a 
third of the infants were born by emergency caesarean section.  
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All infants were 35 weeks or less gestation at birth and most were classified as preterm with 
the lowest gestation being 27 weeks. Only three SGA infants were detected and only one 
VLBW infant had a documented positive HIV PCR.  
 
Extremely low birth weight 
Only one infant was classified as extremely LBW with a weight of 650g. This male infant was 
the result of the third pregnancy of a 33 year old. The mother had been on PI-based HAART 
for 11 weeks prior to developing pre-eclampsia resulting in a preterm birth at 30 weeks 
gestation. 
 
Birth weight versus Gestation 
Figure 3.3.6 Weight for gestational age according to HAART exposure and duration 
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HAART-unexposed women had more SGA (small for gestational age) infants than HAART-
exposed women (43% [59/138] vs. 27% [214/792], P<0.001).  
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More SGA infants were born to HAART-exposed women at RM than at JH (37% [187/505] 
vs. 9% [27/287], P<0.001). 
 
More SGA infants were born to women exposed to late versus early HAART (37% [147/400] 
vs.18% [57/312], P<0.001).  
 
Figure 3.3.7 Weight for gestational age according to HAART regimen and duration 
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Among early HAART-exposure, EFV-exposure was associated with the most SGA infants 
followed by PI-exposure and then NVP-exposure (30% [18/61] vs. 21% [26/123] vs. 10% 
[13/128], P=0.001). 
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Among late HAART-exposure, PI-exposure was associated with more SGA infants followed 
by EFV-exposure and then NVP-exposure (43% [121/280] vs. 32% [6/19] vs. 20% [20/101], 
P=0.001) 
 
Head circumference 
The head circumference measurement at birth was available for 59% (138/233) of HAART-
unexposed infants and 57% (801/1397) of HAART-exposed infants. The mean head 
circumference of HAART-exposed infants was 0.4cm more than HAART-unexposed infants. 
(34.1cm [SD2.2] vs. 33.7cm [SD2.5], P=0.034).  
 
The head circumferences of Infants exposed to early and late HAART were similar (33.0cm 
[SD2.4] vs. 34.3cm [SD2.1], P=0.20). 
 
Among the early HAART-exposed group, infants exposed to NVP had a bigger mean head 
circumference than those exposed to PIs or EFV (34.5cm [SD2.6] vs. 33.9cm [SD2.4] vs. 
33.5cm [SD1.9], P=0.006). )  In the late HAART-exposed group, mean head circumferences 
did not differ across PI, NVP or EFV-based regimens (34.1cm [SD2.0] vs. 34.6cm [SD2.3] vs. 
33.8cm [SD2.0], P=0.10). 
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Infant HIV status 
Infant HIV status determined by DNA PCR at 6 weeks of age was available for 82% 
(191/233) of HAART-unexposed and 59% (828/1397) of HAART-exposed infants.  
 
Rate of HIV positive tests among those tested was almost fourfold higher in the HAART-
unexposed versus HAART-exposed infants (19% [37/191] vs. 5% [45/828], P<0.001). Infants 
exposed to late HAART were five times more likely to test HIV positive than those exposed to 
early HAART (10% [31/316] vs. 2% [8/350], P<0.001).  
 
Among the early and late HAART-exposed groups, HIV positive testing rates were similar for 
PI, NVP and EFV exposure (1% [1/160] vs. 4% [6/154] vs. 1% [1/88], P=0.22 for early and 
8% [17/214] vs.15% [17/214] vs. 7% [1/15], P=0.17 for late). 
 
Summary: Perinatal characteristics and infant outcomes 
The mean duration of HAART was 9.7 weeks; 18.4 weeks and 5.8 weeks for early and late 
HAART respectively. Women exposed to early EFV-based HAART had a longer median 
duration of HAART than other regimens. Most deliveries in the study were vaginal and 
women exposed to PI-based HAART were most likely to have vaginal deliveries. HAART-
exposure was associated with increased preterm birth but PI-based HAART did not have an 
increased risk compared to other regimens. HAART-exposure was not associated with 
increased risk of LBW because HAART-unexposed women had increased risk of SGA 
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infants. Infants exposed to HAART had higher head circumferences and lower HIV rates than 
HAART-unexposed infants. 
Table 3.4.1 Association of demographic and maternal health variables with low birth weight (LBW) 
among HIV-negative infants 
Variable 
Category 
Variable  Low birth 
weight 
infants in all 
participants  
n/N (%LBW) 
P Low birth 
weight 
infants in 
HAART-
unexposed  
 n/N 
(%LBW)   
P Low birth 
weight 
infants in 
HAART-
exposed 
group n/N 
(%LBW)   
P Low birth 
weight 
infants in 
early 
HAART n/N 
(%LBW)   
P Low birth 
weight 
infants 
with late 
HAART n/N 
(%LBW) 
P  
Total Total  173/804 (22)  36/152 (24)  137/652 (21)  69/298 (23)  52/276 (19)  
D
e
m
o
g
ra
p
h
ic
s
 
Maternal age:  
     16-24 
     25-29 
     30-34 
     ≥35 
 
21/123 (17) 
42/235 (18) 
61/270 (23) 
39/130 (30) 
 
 
 
 
0.029 
 
5/27 (19) 
6/31 (19) 
12/41 (29) 
4/11 (36) 
 
 
 
 
0.51 
 
16/96 (17) 
36/204 (18) 
49/229 (21) 
35/119 (29) 
 
 
 
 
0.056 
 
7/46 (15) 
18/93 (19) 
27/104 (26) 
16/51 (31) 
 
 
 
 
0.19 
 
8/42 (19) 
13/85 (15) 
19/99 (19) 
12/50 (24) 
 
 
 
 
0.66 
Race group:  
  Black 
  Mixed 
ancestry 
  Indian/White 
 
62/299 (21) 
5/8 (63) 
0/3 (0) 
 
 
 
  0.012 
 
7/19 (37) 
1/2 (50) 
 
 
 
0.72 
 
55/280 (20) 
4/6 (67) 
0/3 (0) 
 
 
 
0.012           
 
34/158 (22) 
4/5 (80) 
0/0 (0) 
 
 
 
0.002 
 
14/74 (19) 
0/1 (0) 
0/2 (0) 
 
 
 
0.71 
S
u
b
s
ta
n
c
e
 
A
b
u
s
e
 Smoked in 
pregnancy:  4/23 (17) 0.79 1/4 (25) 0.92 3/19 (16) 0.73 3/13 (23) 0.77 0/6 (0) 0.25 
Alcohol use 
in pregnancy:  4/24 (17) 0.72 1/5 (20) 0.85 3/19 (16) 0.74 1/11 (18) 0.90 1/6 (17) 0.93 
H
IV
 d
is
e
a
s
e
 
WHO stage:  
  Stage 1 or 2       
  Stage 3 or 4 
 
40/280 (14) 
25/95 (26) 
 
 
0.007 
 
0/2 (0) 
0/0 (0)  
 
40/278 (14) 
25/95 (26) 
 
 
0.008 
 
15/105 (14) 
13/47 (28) 
 
 
0.049 
 
18/147 (12) 
10/34 (29) 
 
 
0.013 
CD4 cell 
count: cells/mm3  
    0-50 
    50-100  
    100-150 
    150-200 
    200-250 
 
 
21/62 (34) 
38/112 (34) 
37/177 (21) 
40/237 (17) 
37/216 (17) 
 
 
 
 
 
 
<0.001 
 
 
2/5 (40) 
5/16 (31) 
5/19 (26) 
8/41 (20) 
16/71 (23) 
 
 
 
 
 
 
0.78 
 
 
19/57 (33) 
33/96 (34) 
32/158 (20) 
32/196 (16) 
21/145 (14) 
 
 
 
 
 
 
<0.001 
 
 
12/31 (39) 
21/52 (40) 
16/68 (24) 
15/85 (18) 
5/62 (8) 
 
 
 
 
 
 
<0.001 
 
 
3/17 (18) 
10/37 (27) 
12/73 (16) 
15/92 (16) 
12/57 (21) 
 
 
 
 
 
 
0.65 
H
e
a
lt
h
 S
ta
tu
s
 
Hypertension   17/52 (33) 0.029 1/9 (11) 0.36 16/43 (37) 0.004 10/19 (53) 0.001 4/19 (21) 0.75 
Diabetes 
history  0/3 (0) 0.37 0/1 (0) 0.58 0/2 (0) 0.47 0/1 (0) 0.59 0/1 (0) 0.63 
Haemoglobin   
    7-11gm/dl  
    <7gm/dl 
 
39/209 (19) 
4/8 (50) 
 
 
0.083 
 
6/36 (17) 
0/1 (0) 
 
 
0.73 
 
33/173 (19) 
4/7 (57) 
 
 
0.051 
 
11/62 (23) 
3/3 (100) 
 
 
0.004 
 
14/82 (17) 
1/3 (33) 
 
 
0.51 
Syphilis 
serology:  
 positive RPR*  
 
7/18 (39) 
 
0.068 
 
1/3 (33) 
 
0.63         
 
6/15 (40) 
 
0.074 
 
3/6 (50) 
 
0.16 
 
2/7 (29) 
 
0.47 
R
e
p
ro
d
u
c
ti
v
e
 
H
e
a
lt
h
 Previous 
miscarriage 17/75 (23) 0.65 3/14 (21) 0.79 14/61 (23) 0.52 9/37 (24) 0.86 3/20 (15) 0.88 
Previous 
preterm birth 7/29 (24) 0.59 0/8 (0) 0.097 7/21 (33) 0.089 2/7 (29) 0.63 4/13 (31) 0.16 
*RPR – rapid plasma reagin 
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3.4 ASSOCIATION OF STUDY VARIABLES WITH LOW BIRTH WEIGHT 
AMONG HIV NEGATIVE INFANTS (TABLE 3.4.1) 
3.4.1 HIV status of Infants 
Among infants with known HIV status, HIV positive infants had higher rates of LBW than HIV 
negative infants (33% [24/73] vs. 22% [173/804], P=0.038). 
 
Among HAART-unexposed infants, those with positive HIV status were associated with LBW 
(41% [16/39] vs. 24% [36/152], P=0.050).  Among HAART-exposed infants, slightly more 
positive infants were LBW but this was not significant (24% [8/34] vs. 21% [137/652], 
P=0.73). No association between positive HIV status and LBW was found in early HAART-
exposed (P= 0.208) nor late HAART-exposed (P=0.74) groups. 
 
When all infants of unknown HIV status were compared to those with negative HIV status, 
similar rates of LBW were detected (24% [9/37] vs. 24% [36/152], P=0.935).  
 
The remainder of the results in this section refers to infants with known HIV negative status. 
Infants with positive and unknown HIV status were removed before analysis due to the 
association of HIV and LBW [48]. 
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3.4.2 Maternal demographic variables  
(Table 3.4.1) 
  
Maternal age 
On comparison of the ages of women with negative infants, the highest rates of LBW 
occurred in women of 35 years or older (30% [39/130], P=0.029).  When ages in individual 
groups were compared, this finding was most significant in the HAART-exposed infants, 
where 29% (35/119) of women 35 years or older had LBW infants compared to 19% 
(101/529) of younger women (P=0.02).  
 
Race group 
Although most women in the study were black, the small number of women with mixed 
ancestry had the highest proportion of LBW infants (63% [5/8], P=0.012). No Indian or white 
infants had LBW and 21% (62/299) of black infants were LBW. 
 
3.4.3 Substance use 
Smoking 
Smoking was not associated with LBW with smokers and non-smokers having similar 
proportions of LBW negative infants (17% [4/23] vs. 20% [93/474], P=0.79).  
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Alcohol 
Alcohol use was not associated with LBW and the proportion of LBW infants was similar 
whether women used alcohol or not (17% [4/24] vs. 20% [94/478], P=0.72). 
 
3.4.4 HIV Disease 
CD4 cell count 
Among women with negative infants, CD4 cell counts below 100cells/mm3 were associated 
with LBW (34% [59/174] vs. 18% [114/630], P<0.001). 
 
Among HAART-unexposed women, no CD4 cell count range was associated with LBW 
(P=0.78) but a trend of increasing rates of LBW with CD4 decline was evident.  
Figure 3.4.1 LBW infants per CD4 cell count category according to HAART exposure 
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Among HAART-exposed women, those with CD4 cell counts less than 100cells/mm3 had 
more LBW infants than those with higher CD4 cell counts (34% [52/153] vs. 17% [85/499], 
P<0.001). This trend was still significant among women exposed to early HAART (40% 
[33/83] vs. 17% [36/215], P<0.001) but not late HAART (24% [13/54] vs. 18% [39/222], 
P=1.20).  
 
Figure 3.4.2 LBW infants per CD4 cell count category according to HAART duration 
LBW infants per CD4 cell count 
category according to HAART duration
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WHO clinical stage 
Among HAART-exposed women those with more advanced HIV were most at risk for LBW 
negative infants, with WHO clinical stage 4 women having higher rates of LBW than WHO 
clinical stages 3 and 2 and WHO clinical stage 1 women having the lowest rate of LBW (36% 
[8/22] vs. 23% [17/73] vs. 24% [12/50] vs. 12% [28/230], P=0.004). 
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Figure 3.4.3 Association of LBW with WHO stage 
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Although a similar distribution was found among early HAART-exposed women (see figure 
3.4.3), the P value was not significant when each of the 4 WHO clinical stages were 
compared (P=0.90). When the WHO clinical stage 1 and 2 women were compared with WHO 
clinical stage 3 and 4 women , the latter group were more likely to have LBW infants (14% 
[15/105] vs. 28% [13/47], P= 0.049).  
 
Among Late HAART-exposed infants, an association of LBW with advanced WHO clinical 
stage was also detected (57% stage4 [4/7] vs. 22% stage3 [6/27] vs. 28% stage2 [7/25] vs. 
9% stage1 [11/122], P=0.001). 
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3.4.5 Health Status 
Hypertension 
When all study women with negative infants were combined, hypertension was associated 
with LBW (33% [17/52] vs. 20% [102/516], P=0.029). An association between hypertension 
and LBW was found in HAART-exposed (37% [16/43] vs. 19% [82/435], P=0.004) and early 
HAART-exposed women (53% [10/19] vs. 20% [42/210], P=0.001). The association between 
hypertension and LBW was not evident in the HAART-unexposed and late-HAART exposed 
groups which had small numbers of hypertensive women (P=0.36 and 0.75 respectively). 
 
Diabetes History  
Incidence of diabetes was very low across all study groups and diabetic history was not 
associated with LBW among all women (0% [0/3] vs. 21% [120/569], P=0.37) nor in any of 
the study groups. 
 
Haemoglobin 
Among all women, anaemia was not associated with LBW (20% [43/217] vs. 22% [55/246], 
P=0.50). When women were divided according to haemoglobin values below and above 
7gm/dl, women in the former group tended to have higher rates of LBW and the P value 
approached significance (50% [4/8] vs. 21% [94/455], P=0.07).  
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No relationship between anaemia and LBW was found in HAART-unexposed women.  Only 
one woman in this group had severe anaemia (P=0.73). Among HAART-exposed women, 
those with severe anaemia had the highest proportion of LBW infants (57% [4/7] vs. 21% 
[82/393], P=0.04).  
 
Among early HAART-exposed women, severe anaemia was associated with LBW (100% 
[3/3] vs. 20% [33/163], P=0.001.This association was not found among late HAART-exposed 
women (33% [1/3] vs.20% [35/172], P=0.50). 
 
Syphilis serology 
Among all women, those with a positive RPR had a higher rate of LBW than those with a 
negative RPR but this was not significant (39% [7/18] vs. 21% [105/502], P=0.068). Among 
the study groups, no clear association with RPR positive result and LBW could be proven 
 
3.4.6 Reproductive Health 
Previous Miscarriage 
Women who had experienced a previous miscarriage had a similar rate of LBW to those who 
had not (23% [17/75] vs. 20% [85/417], P=0.65). Previous miscarriage was not associated 
with LBW in any of the study groups. 
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Previous Preterm birth 
Among all women, those with previous preterm birth were not associated with LBW when 
compared with women with no such event (24% [7/29] vs. 20% [78/391], P=0.59). No 
association between previous preterm birth and LBW was found in any of the study groups. 
 
Summary of maternal factors associated with LBW 
Among women in this study, maternal factors associated with infant LBW included maternal 
age above 35 years, mixed ancestry (although the numbers were small), CD4 cell count 
below 100cells/mm3, WHO clinical stage 4 HIV disease and hypertension. Trends of 
increased LBW were detected in women with anaemia and positive syphilis serology but 
these were not significant. The numbers of women who were diabetic, smoked, used alcohol, 
had a previous miscarriage or had a previous preterm birth were small and no association 
with LBW and these variables was detected.  
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Table 3.4.2 Association of HAART and infant outcome variables with low birth weight (LBW) among HIV-negative infants 
Variable 
Category 
Variable 
 
LBW infants in 
all participants 
 
n/N (% LBW) 
P 
value 
 
 
 
LBW infants in 
HAART-
unexposed 
 
n/N (% LBW) 
P 
value 
 
 
LBW infants in 
HAART-
exposed 
 
n/N (% LBW) 
P 
value 
 
 
LBW infants in early 
HAART-exposed  
 
n/N (% LBW) 
P 
value 
 
 
LBW infants in 
late HAART-
exposed 
 
 n/N (% LBW) 
P 
value 
 
 
Total Total  173/804 (22)  36/152 (24)  137/652 (21)  69/298 (23)  52/276 (19)  
HAART 
HAART regimen: 
   unexposed 
   all HAART-exposed 
   PI-based HAART 
   NVP-based HAART 
   EFV-based HAART 
 
36/152 (24) 
137/652 (21) 
59/322 (18) 
44/238 (18) 
34/92 (37) 
 
 
0.54 
 
 
0.001 
 
36/152 (24) 
 
 
 
137/152 (24) 
59/322 (18) 
44/238 (18) 
34/92 (37) 
 
 
 
 
 
<0.001 
 
 
69/298 (24) 
18/104 (17) 
21/121 (17) 
30/73 (41) 
 
 
 
 
 
<0.001 
 
 
52/276 (19) 
33/197 (17) 
16/66 (24) 
3/13 (23) 
 
 
 
 
 
0.37 
Duration of HAART:  
   0-3 weeks 
   4-7 weeks 
   8-14 weeks 
   15-29 weeks 
   >30 weeks 
 
28/117 (24) 
16/129 (12) 
28/153 (18) 
16/112 (14) 
32/87 (37) 
 
 
 
 
 
<0.001 
 
 
  
 
28/117 (24) 
16/129 (12) 
28/153 (18) 
16/112 (14) 
32/87 (37) 
 
 
 
 
 
<0.001 
 
12/61 (20) 
14/101 (14) 
30/82 (37) 
 
 
 
 
 
0.001 
 
 
20/88 (23) 
12/94 (13) 
15/83 (18)         
 
 
 
 
 
0.22 
Infant 
Outcomes 
Infant gender:  
   female 
   male 
 
79/390 (20) 
80/373 (21) 
 
 
0.69 
 
16/75 (21) 
20/75 (27) 
 
 
0.44 
 
63/315 (20) 
60/298 (20) 
 
 
0.97 
 
32/151 (21) 
31/133 (23) 
 
 
0.67 
 
28/137 (20) 
21/135 (16) 
 
 
0.30 
Preterm birth:  
   no 
   yes 
 
102/601 (17) 
34/66 (52) 
 
 
<0.001 
 
18/90 (20) 
3/4 (75) 
 
 
0.01 
 
84/511 (16) 
31/62 (50) 
 
 
<0.001 
 
32/218 (15) 
23/43 (53) 
 
 
<0.001 
 
47/263 (18) 
5/13 (38) 
 
 
0.064 
Growth 
   AGA 
   SGA 
   LGA 
 
42/421 (10) 
83/174 (48) 
0/26 (0) 
 
 
 
<0.001 
 
3/55 (5) 
18/38 (47) 
0/1 (0) 
 
 
 
<0.001 
 
39/366 (11) 
65/136 (48) 
0/25 (0) 
 
 
 
<0.001 
 
25/179 (14) 
24/42 (57) 
0/19 (0) 
 
 
 
<0.001 
 
12/172 (7) 
40/93 (43) 
0/6 (0) 
 
 
 
<0.001 
 
PI  -protease inhibitor; NVP –nevirapine; EFV- efavirenz; AGA – appropriate for gestational age; SGA – small for gestational age; LGA – large for gestational age 
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3.4.7 HAART exposure  
(Table 3.4.2) 
A similar rate of LBW was found in HAART-unexposed and HAART-exposed negative infants 
(24% [36/152] vs. 21% [137/652], P=0.54).  
  
Early HAART-exposed infants were not more at risk for LBW than late HAART-exposed 
infants (24% [69/292] vs. 19% [52/276], P=0.20). 
 
EFV-exposure was associated with LBW compared to PI-exposure and NVP-exposure (37% 
[34/92] vs. 18% [59/322] vs. 18% [44/238], P=0.001). Early EFV-exposure was particularly 
associated with LBW (41% [30/73] vs. 17% [18/104] vs. 17% [21/121], P<0.001) while late 
EFV-exposure was not (23% [3/13] vs. 17% [33/197] vs. 24% [16/66], P=0.37). 
 
Duration of HAART exposure 
The risk of LBW according to duration of HAART exposure had a bimodal distribution with 
the highest rates of LBW found in women who received HAART for longest (>30 weeks) and 
shortest (0 to 3 weeks) durations (37% [32/87] and 24% [28/117]). The lowest rate of LBW 
was found in women who received HAART for 4-7 weeks followed by the women who 
received 15-29 weeks and then 8-14 weeks of HAART (12% [16/129] vs. 14% [16/112]  
vs.18% [28/153], P<0.001). (See graph). 
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Figure 3.4.4 Association of LBW with WHO stage 
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3.4.8 Infant outcomes 
Infant gender 
Rates of LBW for male versus female negative infants did not differ across all the groups with 
20% (79/390) of all female infants and 21% (80/373) of all male infants having LBW 
(P=0.69).  
 
Preterm birth 
As expected, negative preterm Infants had a higher rate of LBW than their term counterparts 
and this was true across all groups.  
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Growth 
As expected, infants with SGA were most associated with LBW versus those with AGA or 
LGA and this was true across all groups. 
 
Summary of association of Infant and HAART variables with LBW 
HAART-exposed women had similar rates of LBW compared to HAART-unexposed women. 
When different durations of HAART exposure were compared, women exposed to less than 
7 weeks or more than 30 weeks of HAART were most likely to have LBW infants. Among 
HAART exposed women, those exposed to early EFV-based regimens had the highest rates 
of LBW.  
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3.5 ASSOCIATION OF STUDY VARIABLES WITH PRETERM BIRTH 
3.5.1 Maternal demographic variables  
(Table 3.5.1) 
 Maternal age 
On comparison of all women, no particular age range was found to be associated with 
preterm births. In women exposed to early HAART, the highest rates of preterm birth 
occurred in women of 35 years or older (32% [23/71], P=0.031).   
 
Race group 
No clear association with race group and preterm birth was detected. 
 
3.5.2 Substance use 
Smoking 
Smoking was not associated with preterm birth with smokers and non-smokers having similar 
proportions of preterm infants (10% [3/31] vs. 12% [88/750], P=0.73).  
 
Alcohol 
Alcohol use was not associated with preterm birth and the proportion of preterm infants was 
similar whether women used alcohol or not (10% [3/30] vs. 12% [88/760], P=0.79). 
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3.5.3 HIV Disease 
CD4 cell count 
Women with CD4 cell counts below 100cells/mm3 were associated with preterm birth (20% 
[47/235] vs. 11% [98/858], P=0.001). 
 
WHO clinical stage 
WHO clinical stage was only available for HAART-exposed women. Women with WHO stage 
4 were most at risk for preterm infants (26% [9/35], P=0.035).  
 
3.5.4 Health Status 
Tuberculosis 
TB history was only available for 121 HAART-exposed women. No association between 
preterm birth and TB was detected (28% [15/54] vs. 21% [52/67], P=0.28. 
 
Hypertension 
When all study women were combined, hypertension was not associated with preterm birth 
(17% [14/83] vs. 12% [99/794], P=0.26) but an association between hypertension and 
preterm birth was found in early HAART-exposed women (38% [11/29] vs. 19% [56/290], 
P=0.019). 
 
Diabetes History  
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Incidence of diabetes was very low across all study groups and diabetic history was not 
associated with preterm birth among all women (0% [0/4] vs. 13% [115/876], P=0.44) nor in 
any of the study groups. 
 
Haemoglobin 
Anaemia was not associated with preterm birth among any of the study groups. 
  
Syphilis serology 
Among the study groups, no clear association with RPR positive result and preterm birth 
could be proven 
 
3.5.5 Reproductive Health 
Previous Miscarriage 
Women who had experienced a previous miscarriage had a similar rate of preterm birth to 
those who had not (13% [16/127] vs. 11% [68/642], P=0.51). Previous miscarriage was not 
associated with preterm birth in any of the study groups. 
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Previous Preterm birth 
Among all women, those with previous preterm birth were associated with preterm birth when 
compared with women with no such event (20% [10/50] vs. 9% [56/626], P=0.011). This 
association was also detected in women exposed to HAART (26% [9/34] vs. 10% [50/501], 
P=0.003) and women exposed to early HAART (42% [5/12] vs. 13% [23/179], P=0.006).  
 
Summary of maternal factors associated with preterm birth 
Among women in this study, maternal factors associated with infant preterm birth included 
low CD4 cell count, advanced WHO clinical stage and previous preterm birth.  No association 
with preterm birth was detected in women who ever had TB, were anaemic, were diabetic, 
had positive syphilis serology, smoked, used alcohol or had a previous miscarriage. 
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Table 3.5.1 Association of demographic and maternal health variables with preterm birth 
Variable 
Categor
y 
Variable  Preterm birth 
infants in all 
participants  
n/N (% prem) 
P Preterm 
birth 
infants in 
HAART-
unexpos
ed  
 n/N (% 
prem)   
P Preterm birth 
infants in 
HAART-
exposed 
group n/N (% 
prem)   
P Preterm 
birth 
infants in 
early 
HAART n/N 
(% prem)   
P Preterm 
birth 
infants with 
late HAART 
n/N (% 
prem) 
P  
Total Total  145/1093 (13)  7/147 (5)    81/389 (21)  21/427 (5)  
D
e
m
o
g
ra
p
h
ic
s
 
Maternal age:  
     16-24 
     25-29 
     30-34 
     ≥35 
19/182 (10) 
43/345 (12) 
52/369 (14) 
31/192 (16) 0.39 
1/30 (3) 
4/45 (9) 
1/51 (2) 
1/20 (5) 0.44 
18/152 (12) 
39/300 (13) 
51/318 (16) 
30/172 (17) 0.37 
11/53 (21) 
19/131 (15) 
28/131 (21) 
23/71 (32) 
 
 
 
 
0.031 
1/77 (1) 
12/128 (9) 
7/146 (5) 
1/75 (1) 0.022 
Race group:  
  Black 
  Mixed ancestry 
  Indian/White 
86/453 (19) 
2/11 (18) 
0/4 (0) 0.63 
0/29 (0) 
1/2 (50) 
0/0 (0) <0.001 
86/424 (20) 
1/9 (11) 
0/4 (0) 0.48 
 
50/217 (23) 
1/5 (20) 
0/0 (0) 
 
 
 
0.873 
10/120 (8) 
0/2 (0) 
0/3 (0) 0.80 
S
u
b
s
ta
n
c
e
 A
b
u
s
e
 Smoked in 
pregnancy:  
   yes 
   no 
3/31 (10) 
88/750 (12) 0.73 
1/6 (17) 
5/128 (4) 0.14 
2/25 (8) 
83/622 (13) 0.44 
2/15 (13) 
46/243 (19) 0.59 
0/7 (0) 
13/305 (4) 0.58 
Alcohol use in 
pregnancy:  
   Yes 
   no 
3/30 (10) 
88/760 (12) 0.79 
1/7 (14)  
6/131 (5) 0.25 
2/23 (9) 
82/629 (13)  
1/15 (7) 
47/246 (19) 0.23 
0/7 (0) 
13/308 (4) 0.58 
H
IV
 d
is
e
a
s
e
 
WHO stage:  
  Stage 1  
  Stage 2       
  Stage 3  
  Stage 4 
34/310 (11) 
7/64 (11) 
19/104 (18) 
9/35 (26) 0.035 
No 
observati
ons  
34/310 (11) 
7/64 (11) 
19/104 (18) 
9/35 (26) 0.035 
21/111 (19) 
5/25 (20) 
11/43 (26) 
5/15 (33) 0.55 
6/180 (3) 
0/35 (0) 
2/43 (5) 
2/12 (17) 0.066 
CD4 cell count: 
cells/mm
3  
    0-50 
    50-100  
    100-150 
    150-200 
    200-250 
15/77 (19) 
32/158 (20) 
36/253 (14) 
32/318 (10) 
30/287 (10) 0.006 
0/2 (0) 
2/16 (13) 
3/20 (15) 
1/43 (2) 
1/66 (2) 0.063 
15/75 (20) 
30/142 (21) 
33/233 (14) 
31/275 (11) 
29/221 (13) 0.050 
13/40 (33) 
19/63 (30) 
18/91 (20) 
14/107 (13) 
17/88 (19) 0.03 
1/28 (4) 
4/62 (6) 
7/108 (6) 
5/136 (4) 
4/93 (4) 0.83 
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Table 3.5.1 (continued) 
Variable 
Category 
Variable  
 
Preterm birth 
infants in all 
participants  
n/N (% prem) 
 
P 
 
Preterm 
birth 
infants in 
HAART-
unexposed  
 n/N (% 
prem)   
 
P 
 
Preterm birth 
infants in 
HAART-
exposed 
group n/N (% 
prem)   
 
P 
 
Preterm 
birth 
infants in 
early 
HAART n/N 
(% prem)   
 
P 
 
Preterm 
birth 
infants 
with late 
HAART n/N 
(% prem) 
 
P  
 
Total Total 
145/1093 (13)  7/147 (5)    81/389 (21)  21/427 (5)  
H
e
a
lt
h
 S
ta
tu
s
 
Hypertension  
   yes 
   no  
14/83 (17) 
99/794 (12) 0.26 
0/16 (0) 
6/122 (5) 0.36 
14/67 (21) 
93/672 (14) 0.12 
11/29 (38) 
56/290 (19) 0.019 
2/27 
15/314 0.54 
Diabetes 
history 
   yes 
   no 
0/4 (0) 
115/876 (13) 0.44 
0/1 (0) 
7/139 (5) 0.82 
0/3 (0) 
108/740 (15) 0.118 
0/1 (0) 
67/318 (21) 0.61 
0/2 (0) 
17/432 (5) 0.75 
Haemoglobin  
    >11gm/dl  
    7-11gm/dl  
    <7gm/dl 
51/361 (14) 
40/319 (13) 
2/13 (15) 0.81 
2/43 (5) 
1/53 (2) 
0/2 (0) 0.71 
49/318 (15) 
39/266 (15) 
2/11 (18) 0.93 
1/4 (25) 
20/90 (22) 
31/133 (23) 0.98 
5/146 (3) 
7/134 (5) 
1/6 (17) 0.27 
Syphilis 
serology:  
 positive RPR* 
 negative RPR  
7/34 (21) 
90/765 (12) 0.12 
0/3 (0) 
7/129 (5) 0.68 
7/31 (23) 
83/636 (13) 0.13 
3/10 (30) 
44/216 (20) 0.46 
0/11 (0) 
15/328 (5) 0.47 
R
e
p
ro
d
u
c
ti
v
e
 H
e
a
lt
h
 
Gravidity 
   gravida 1 
   gravida 2 
   gravida 3 
   gravida>4 
9/127 (7) 
47/339 (14) 
37/273 (14) 
21/163 (13) 0.24 
1/21 (5) 
3/52 (6) 
3/42 (7) 
0/27 (0) 0.59 
8/106 (8) 
44/287 (15) 
34/231 (15) 
21/136 (15) 0.22 
7/42 (17) 
25/116 (22) 
18/101 (18) 
17/66 (26) 0.57 
1/57 (2) 
9/140 (6) 
5/98 (5) 
2/59 (3) 0.52 
Previous 
miscarriage 
   yes 
   no 
16/127 (13) 
68/642 (11) 0.51 
3/27 (11) 
4/112 (4) 0.11 
13/100 (13) 
64/530 (12) 0.80 
10/52 (19) 
31/197 (16) 0.55 
2/38 (5) 
13/272 (5) 0.90 
Previous 
preterm birth 
   yes 
   no 
10/50 (20) 
56/626 (9) 0.011 
1/16 (6) 
6/125 (5) 0.80 
9/34 (26) 
50/501 (10) 0.003 
5/12 (42) 
23/179 (13) 0.006 
2/18 (11) 
10/263 (4) 0.14 
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3.5.6 HAART exposure  
(Table 3.5.2) 
A higher rate of preterm birth was found in HAART-exposed compared to HAART-unexposed 
infants (15% [138/946] vs. 5% [7/147], P<0.001).  
  
Early HAART-exposed infants were more at risk for preterm birth than late HAART-exposed 
infants (21% [81/389] vs. 5% [21/427], P<0.001). 
 
PI-exposure was less associated with preterm birth than NVP and EFV-exposure (9% 
[44/474] vs. 19% [63/336] vs. 23% [31/136], P<0.001).  
 
Duration of HAART exposure 
Women who had received HAART for more than 30 weeks were at highest risk for preterm 
birth (22% [20/92], P=0.002). (see table 4.2)  
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Table 3.5.2 Association of HAART and infant outcome variables with preterm birth  
 
PI -protease inhibitor; NVP –nevirapine; EFV- efavirenz;  
 
 
3.5.7 Infant outcomes 
Infant gender 
Rates of preterm birth  for male versus female negative infants did not differ across all the 
groups with 12% (60/501) of all female infants and 12% (60/500) of all male infants having 
preterm birth (P=0.99).  
 
V
a
ri
a
b
le
 C
a
te
g
o
ry
 
Variable 
 
Preterm 
infants in all 
participants 
 
 
 
n/N (% prem) 
P 
value 
 
 
 
Preterm 
infants in 
HAART-
unexposed 
 
n/N  
(% prem) 
P 
value 
 
 
Preterm 
infants in 
HAART-
exposed 
 
n/N 
 (% prem) 
P 
value 
 
 
Preterm 
infants in 
early 
HAART-
exposed  
 
n/N  
(% prem) 
P 
value 
 
 
Preterm 
infants in 
late 
HAART-
exposed 
 
 n/N 
 (% prem) 
P 
value 
 
 
T
o
ta
l Total  
145/1093 (13)  7/147 (5)  
138/946 
(15)  81/389 (21)  21/427 (5)  
H
A
A
R
T
 HAART regimen: 
   unexposed 
   all HAART-exposed 
   PI-based HAART 
   NVP-based HAART 
   EFV-based HAART 
 
7/147  (5) 
138/946 (15) 
44/474 (9) 
63/336 (19) 
31/136 (23) <0.001 
7/147 (5) 
 
 
 
  
138/946 
(15) 
44/474 (9) 
63/336 (19) 
31/136 (23) <0.001 
81/389 (21) 
19/131 (15) 
40/167 (24) 
22/91 (24) 
 
 
 
 
 
0.091 
21/427 (5) 
9/290 (3) 
11/116 (9) 
1/21 (5) 0.027 
Duration of HAART:  
   0-3 weeks 
   4-7 weeks 
   8-14 weeks 
   15-29 weeks 
   >30 weeks 
21/169 (12) 
9/172 (5) 
25/214 (12) 
15/141 (10) 
20/92 (22) 0.002   
21/169 (12) 
9/172 (5) 
25/214 (12) 
15/141 (10) 
20/92 (22) 0.002 
8/21 (38) 
2/16 (13) 
22/88 (25) 
15/134 (11) 
20/91 (22) 0.010 
10/142 (7) 
7/148 (5) 
3/12 (2) 
0/4 (0) 
 0.36 
In
fa
n
t 
O
u
tc
o
m
e
s
 Infant gender:  
   female 
   male 
60/501 (12) 
60/500 (12) 0.99 
3/71 (4) 
4/74 (5) 0.74 
57/430 (13) 
56/426 (13) 0.96 
38/185 (20) 
31/173 (18) 0.53 
10/205 (5) 
9/204 (4) 0.82 
Low Birth Weight:  
   no 
   yes  
57/794 (7) 
61/217 (28) <0.001 
2/104 (2) 
4/40 (10) 0.03 
55/635 (8) 
57/177 (32) <0.001 
25/267 (9) 
35/74 (47) <0.001 
12/331 (4) 
7/76 (9) 0.037 
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Low birth weight 
As expected, low birth weight infants had a higher rate of preterm births than their heavier 
counterparts and this was true across all groups.  
 
Summary of association of Infant and HAART variables with preterm birth 
HAART-exposed women had higher rates of preterm birth compared to HAART-unexposed 
women. When different durations of HAART exposure were compared, women exposed to 
more than 30 weeks of HAART were most likely to have preterm infants. Among HAART 
exposed women, those exposed to NNRTI-based regimens had the highest rates of preterm 
birth.  
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3.6 MULTIVARIATE ANALYSIS OF LBW 
(Table 3.6) 
Table 3.6 Multivariate logistic regression showing risk factors for LBW in HAART-exposed women. 
 
 
Variable 
 
Low Birth Weight (<2500g) 
 
Early HAART Late HAART 
 
Univariate analysis Multivariate analysis Univariate Analysis Multivariate Analysis 
 OR CI (95%) 
P 
value 
AO
R CI 
P 
value OR CI (95%) 
P 
value AOR CI P value 
HAART-unexposed 1.00   1.00   1.00   1.00   
HAART-exposed 
   PI-based HAART 
   NVP-based HAART 
   EFV-based HAART 
 
0.67 
0.68 
2.25 
 
0.36-1.27 
0.37-1.23 
1.24-4.09 
0.22 
0.20 
0.008 
 
0.44 
0.37 
1.00 
 
0.19-1.05 
0.17-0.83 
0.45-2.23 
 
0.064 
0.015 
1.0 
 
0.65 
1.03 
0.97 
0.38-1.10 
0.52-2.03 
0.25-3.70 
0.11 
0.93 
0.96 
 
0.52 
1.02 
0.55 
 
0.26-1.05 
0.46-2.31 
0.10-2.97 
 
0.068 
0.94 
0.49 
CD4 cell count 
   per category 
increase* 0.70 0.59-0.83 <0.001 0.58 0.46-0.73 <0.001 0.94 0.77-1.15 0.54 0.92 0.71-1.18 0.50 
Maternal age 
   per year increase 1.06 1.01-1.11 0.015 1.06 1.00-1.12 0.043 1.04 0.99-1.09 0.14 1.04 0.98-1.10 0.16 
Hypertension 2.39 1.06-5.37 0.035 2.38 0.99-5.73 0.054 0.87 0.31-2.38 0.78 0.72 0.25-2.05 0.53 
  
HAART, antiretroviral therapy; PI, Protease inhibitor; NVP, Nevirapine; EFV, Efavirenz; OR, odds ratio; AOR adjusted odds 
ratio; CI (95%), 95% confidence interval * CD4+ categories (cells/mm3): 0-49, 50-99, 100-149, 150-199 and 200-250 
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3.6.1 Early HAART 
In unadjusted analysis of women exposed to early HAART, EFV-based HAART and 
hypertension were the only variables associated with LBW. After adjusting for regimen type, 
CD4 category, maternal age and hypertension, only hypertension was associated with LBW 
and the association of EFV-based HAART and LBW was no longer detected. A rise in CD4 
category was protective against LBW. Nevirapine-based HAART was associated with a 
reduction in LBW (OR 0.37, 95% CI 0.17-0.83, P=0.02), a similar odds as PI-containing 
regimens (0.44, 95%CI=0.19-1.05). 
 
3.6.2 Late HAART 
No clear associations between the risk factors analysed and LBW were found in the group of 
women exposed to late HAART. Women exposed to PI-based HAART had the lowest AOR 
(adjusted odds ratio) for LBW and the P value approached significance (P=0.068). 
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3.7 MULTIVARIATE ANALYSIS OF PRETERM BIRTH 
Table 3.7 Multivariate logistic regression showing risk factors for preterm birth in HAART-exposed 
women. 
 
Variable 
 
Preterm Birth (<37weeks) 
 
Early HAART Late HAART 
 
Univariate analysis Multivariate analysis Univariate Analysis Multivariate Analysis 
 OR CI (95%) P AOR CI P  OR CI (95%) P AOR CI P 
HAART-
Unexposed 
Exposed: 
  PI-based  
  NVP-based  
  EFV-based   
1.00 
 
3.39 
6.30 
6.40 
 
 
1.38-8.36 
2.72-13.56 
2.60-15.65 
0.008 
<0.001 
<0.001 
1.00 
 
3.00 
5.41 
5.64 
1.07-8.38 
2.14-13.70 
2.09-15.16 
0.036 
<0.001 
0.001 
1.00 
 
0.64 
2.10 
1.00 
0.23-1.76 
0.79-5.59 
0.12-8.56 
0.39 
0.14 
1.00 
1.00 
 
0.70 
1.88 
1.47 
0.23-2.13 
0.61-5.80 
0.15-14.10 
0.53 
0.27 
0.74 
CD4 cell 
count 
0-49cells/mm
3
 
per category 
increase* 
1.00 
 
0.69 0.58-0.83 <0.001 
1.00 
 
0.68 0.55-0.85 0.001 
1.00 
 
0.78 0.57-1.07 0.12 
1.00 
 
0.80 0.55-1.15 0.22 
Maternal age 
  16-24 years 
  25-29 years 
  30-34 years 
  >35 years 
1.00 
0.90 
1.12 
2.12 
0.42-1.89 
0.54-2.33 
0.98-4.57 
0.76 
0.76 
0.056 
1.00 
0.91 
1.08 
2.09 
0.37-2.21 
0.45-2.57 
0.83-5.25 
0.83 
0.86 
0.12 
1.00 
5.35 
2.22 
1.13 
1.2-23.75 
0.46-10.66 
0.16-8.18 
0.027 
0.32 
0.90 
1.00 
9.17 
3.46 
1.91 
1.17-72.0 
0.41-29.45 
0.17-21.66 
0.03
5 
0.26 
0.60 
Hypertension 
  no 
  yes 
1.00
1.83 0.88-3.80 0.11 
1.00 
1.95 0.87-4.36 0.11 
1.00 
0.96 0.22-4.26 0.96 
1.00 
0.84 0.18-3.90 0.83 
 
3.7.1 Early HAART  
In univariate analysis evaluating associations between HAART and preterm birth in all infants 
(regardless of HIV status), significant associations were detected in the early HAART group 
between HAART-exposure (to any HAART-regimen) and maternal CD4 count. Of the 
regimens, NNRTI-based regimens were most associated with preterm birth and this 
association remained in multivariate analysis.  In the early HAART group, every 50 cell rise in 
CD4+ cell count was associated with a 31% decrease in the odds of preterm birth in 
univariate analysis (95% CI 0.58-0.83, P<0.001) and remained significant after multivariate 
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analysis (AOR 0.68, 95% CI 0.55-0.85, P=0.001) . Neither smoking nor alcohol was 
associated with preterm birth in this analysis.  
 
3.7.2 Late HAART 
No clear associations between the risk factors analyzed and LBW were found in the group of 
women exposed to late HAART.  
 
3.8 SUMMARY OF RESULTS  
Among this cohort of women with advanced HIV disease, HAART-exposed women were 
found to be older and have lower immunity than HAART-unexposed women. HAART 
exposed women had increased preterm birth rates and decreased LBW rates compared to 
HAART-unexposed women. HAART-unexposed women had higher rates of SGA infants.  PI-
exposed women did not have increased preterm birth rates compared to other regimens.   
 
Women exposed to EFV-based HAART had the most clinically and immunologically 
advanced HIV disease, the highest rate of TB history and the longest median duration of 
HAART exposure of any regimen. After adjusting for CD4 category, maternal age and 
hypertension EFV-based HAART was not found to be associated with LBW. 
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CHAPTER 4 
 
4.0 DISCUSSION 
4.1 INTRODUCTION 
This study set out to explore birth outcomes associated with in-utero HAART exposure in the 
context of non-research clinical settings in Johannesburg South Africa where women were 
only initiated on HAART if they had advanced immuno-suppression. The hope was to help 
inform HIV clinicians working with pregnant women in similar settings about the safety of the 
regimens available as well as the relationship between duration of regimen and adverse 
outcomes.   
 
4.2 INFANT OUTCOMES 
4.2.1 Gestation 
In this cohort of HIV-infected, immunocompromised women, HAART-exposure was 
associated with an increased risk of preterm birth. This supports previous studies by Lorenzi 
[5], Thorne [7], Cotter [9] and Townsend [17] which demonstrated an association between  
in-utero-HAART exposure and preterm birth. An important difference in our study is that it 
examined this association in women with low immunity thus on the one hand controlling for 
the influence of CD4 cell count on risk for preterm birth but on the other hand making the 
findings applicable to that group only. Additionally, rates of smoking and alcohol use across 
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all our groups were low, unlike many European and North American studies, where rates of 
smoking have ranged from 7.5% to 55% [14,19,34].  A longer exposure to HAART was linked 
with increased risk of preterm birth but since women who initiated HAART after 28 weeks 
had already achieved the third trimester of their pregnancy, this finding should be viewed with 
this in mind.  
 
Contrary to other studies by Lorenzi [5] and Cotter[9], we did not find PI-based HAART to be 
particularly associated with preterm birth compared to other regimens. What may explain this 
finding is that unlike previous studies, PI-exposure was not associated with advanced HIV 
disease, itself a risk factor for preterm birth. Another important difference is that our study 
only used boosted PIs (lopinavir/ritonavir combination) compared to previous studies which 
used mainly unboosted PIs [5, 9]. It is possible that boosted PIs are less likely to influence 
birth outcomes because they allow for lower dosage without compromising drug efficacy and 
therefore have decreased adverse effects. 
 
 In our study NNRTI-exposed women experienced more preterm births than PI-exposed 
women. The women exposed to NNRTIs were more likely to have attended JH and therefore 
had more complicated pregnancies including increased rates of hypertension and previous 
miscarriage. In Addition, efavirenz-exposed women had more advanced HIV than women on 
other regimens, and early efavirenz- exposed women had been on HAART longer than other 
groups (62.7 weeks vs. 16 weeks), both factors put these women at risk for preterm births. In 
multivariate analysis with these co-variates included, there was a small attenuation in the 
odds ratio (from 6.4 to 5.6); however, the association of early efavirenz with preterm delivery 
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remained strongly significant (P=0.001). This explains the dissipation of effects in adjusted 
models.  
 
Unlike Thorne [7] and Townsend’s [17] findings, the rate of extreme preterm birth was not 
significantly increased with HAART-exposure.  However early HAART-exposure was 
associated with higher extreme premature birth rate when compared to late HAART-
exposure. These findings suggest that HAART may pose some risk for extremely premature 
birth but our study was not adequately powered to detect this.  
 
Rates of smoking and alcohol use across all groups were found to be low. No women were 
identified as users of illicit substances. The latter may be expected in a community where 
HIV is predominantly spread through heterosexual contact. Unlike many European and North 
American studies [8, 14, 17, 19, 34] the birth outcomes in our study are not confounded by 
illicit substance use during pregnancy, which is a cause of preterm birth [28]. 
 
 Many of the studies which found an association between preterm birth and HAART exposure 
did not take into account previous preterm birth as a risk factor [7, 13]. An exception to this 
was the study by Cotter [9]. Our study found a higher rate of previous preterm birth in the 
HAART-unexposed women while HAART-exposed women experienced more preterm births 
in their index pregnancy. This suggests HAART as an independent risk factor for preterm 
birth.  
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4.2.2 Birth weight 
The finding of a lower mean birth weight and a higher rate of LBW in HAART-unexposed 
infants seems contradictory to the association of HAART-exposure and preterm birth. 
However, it was found that HAART-unexposed women had higher rates of SGA infants. The 
rate of LBW of all study infants (22%) was higher than the rate of 15% predicted by UNICEF 
[29] for South Africa but for different reasons. HAART-exposed infants were more likely to be 
born preterm while HAART-unexposed infants were more likely to be SGA. While HAART 
caused a mild degree of preterm birth, it was protective against HIV transmission and 
intrauterine growth restriction in infants born to women with low immunity. This highlights the 
importance of HIV positive women with low CD4 cell counts accessing HAART early in 
pregnancy for the sake of their own and their infant’s health. 
 
Many of the factors associated with LBW in this study, such as maternal age, CD4 cell count 
and hypertension, have been reported in previous studies [48]. Despite findings from a 
variety of other settings, in our cohort lopinavir/ritonavir exposure was not associated with 
LBW in early or late HAART-exposed women. We did detect some association of LBW with 
efavirenz, which did not persist after controlling for stage of HIV infection and TB, factors 
linked to poor obstetric outcomes, including LBW [53,54]. Unexpectedly, in the early HAART 
group, nevirapine was found to decrease the odds of LBW. Nevirapine has previously been 
associated with increased risk of LBW [54] as well as found to be neutral with respect to LBW 
[70]. To our knowledge this data is the first to describe a protective effect. This could be due 
to the fact that untreated advanced HIV infection (CD4 count <250 cells/mm3) confers 
increased risk for low birth weight, and initiation of treatment lowers this risk. There could 
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also be site specific reasons why NNRTIs and not PIs were significant in this analysis. 
Women started on NNRTIs tended to be from JH, which handled more complicated 
pregnancies. Therefore, the protective effect of NNRTI on birth weight may be seen in the 
setting of the high risk of LBW in women at JH with both advanced HIV and complicated 
pregnancies. In contrast with previous studies, we did not find associations with LBW and 
previous preterm birth, previous miscarriage, anaemia, and syphilis [28,58].  
 
Only 26 study infants were VLBW. Women with VLBW infants were more likely to be from 
RM, a site that has an integrated approach to the care of HIV-infected infants in the neonatal 
intensive care unit (ICU). CMJH does not have a specific linkage between HIV and neonatal 
ICU care, increasing the likelihood that these infants could have been lost to follow-up and 
not included in the database. In the small group of VLBW infants identified, no association 
was detected with maternal immunological status [48]. Neither HAART duration (early vs. 
late) nor regimen emerged as a risk factor for VLBW. Small numbers of VLBW infants limit 
this analysis.  
 
4.2.3 Head circumference 
In addition to having a higher mean birth weight, HAART-exposed infants had a higher mean 
head circumference than HAART-unexposed infants. This suggests that the HAART –
unexposed infants had a degree of intrauterine growth restriction which affected skull growth 
as well as weight. This resulted in a pattern of symmetrical growth restriction and implies that 
these infants experienced slowing in growth from early on in pregnancy. Therefore our 
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findings suggest that maternal HAART could protect against symmetrical growth restriction in 
foetuses of immunologically suppressed women.  
 
4.2.4 Infant HIV status 
Infants whose mothers missed the opportunity for HAART had a much higher rate of positive 
HIV test than those who accessed HAART (19% vs. 5%, P<0.001). The use of single dose 
NVP among the HAART-unexposed women was not known but probably accounted for their 
transmission rate being slightly lower than some studies of infants with no antiretroviral 
exposure. One such study, the first study to show a reduction in MTCT using AZT, showed 
an HIV transmission rate of 25.5% in its placebo arm [55]. Early HAART was associated with 
a lower rate of HIV positive infants than late HAART (2% vs. 9%, P<0.001). This is congruent 
with the finding that the longer the exposure to HAART, the more time allowed for viral 
suppression and the lower the HIV transmission [56, 57]. No regimen was found to be 
superior in terms of HIV transmission for early or late HAART exposure. 
 
4.3 DESCRIPTION OF STUDY POPULATION 
4.3.1 HAART exposed versus HAART-unexposed 
In this study women exposed to HAART had a mean age 1.4 years older, a lower median 
CD4 count and higher median haemoglobin level than HAART-unexposed women. Possibly, 
older women were more likely to attend antenatal clinic and access HAART than younger 
women. Women with lower CD4 cell counts may have had more clinical stigmata of HIV and 
been more inclined to seek health care for themselves. HAART may have had a protective 
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effect on the development of anaemia during pregnancy but must be seen in the context of 
this study. Many of the HAART-unexposed women had not attended antenatal clinic and not 
received iron and folate supplementation which would also predispose them to lower 
haemoglobin levels. Previously, extremes of maternal age, low CD4 counts and low 
haemoglobin levels have been linked with preterm birth and LBW [28]  After controlling for 
age and CD4 count  in the multivariate analysis, we did not find HAART-exposure to be 
associated with LBW. 
 
Many HAART-unexposed women had not accessed antenatal care and probably had poor 
health seeking behaviour which could have adversely affected the outcomes of their previous 
and current pregnancies. This may have contributed to the slightly higher previous preterm 
pregnancy rate in the HAART-unexposed versus HAART-exposed women (P=0.055). 
Despite having more risk factors such as a higher rate of anaemia and previous preterm 
pregnancy, the HAART-unexposed women had a lower rate of preterm birth than the 
HAART-exposed women. This suggests HAART as an independent risk factor for preterm 
birth. 
 
Women exposed to early HAART had a higher previous miscarriage rate than those exposed 
to late HAART. Previous miscarriage has been identified as a risk factor for preterm delivery 
and could therefore have been a confounder when rates of preterm birth in these groups 
were compared [28, 58].  
 
  118 
In summary, HAART-exposed women were slightly older, had immunologically more 
advanced HIV, fewer previous preterm deliveries and higher haemoglobin values than 
HAART-unexposed women. More women exposed to early HAART were black, and had 
more previous miscarriages than those exposed to late HAART.  
 
4.3.2 Rahima Moosa Hospital versus Charlotte Maxeke Johannesburg 
Academic Hospital  
RM had a greater proportion of women exposed to PI-based HAART than JH due to the 
prescribing protocol at that hospital. The highest rate of PI-used was found in women 
exposed to late HAART since those exposed to early HAART may already have been taking 
NNRTI-based regimens when they found out they were pregnant. 
 
JH had a greater proportion of women exposed to NNRTI-based HAART, most women in the 
late HAART-exposed group using NVP (92% of late HAART) and most women in the early 
HAART-exposed group using EFV (79% of early HAART). This could be because many 
women in the early HAART group were already on EFV when they fell pregnant and only 
presented to clinic subsequent to the first trimester and therefore left on EFV, while the late 
HAART group were mainly initiated on NVP as per that clinic’s protocol.  
 
Almost all (99%) of the women from JH were black due to the areas which refer to this 
hospital housing predominantly black communities. In contrast, RM had a few more women 
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of mixed ancestry and Indian or white women due to the nature of the surrounding 
communities of the hospital. 
 
RM hospital had a greater amount of women in WHO clinical stage 1 (73%) than JH hospital 
(46%, P<0.001). This could be due to JH antenatal clinic being a referral centre for more 
complicated patients as well as pregnant patients from the JH adult antiretroviral clinic. 
Patients attending an ARV clinic tend to have more clinically advanced HIV than women who 
have been identified as HIV positive through antenatal screening. Since most of the RM 
women were on PI-based HAART, this regimen was associated with less advanced HIV than 
other regimens.  
 
A higher rate of alcohol use was detected in HAART-exposed women at JH than RM hospital 
(P=0.001). This result should be viewed in the context of limited data and low rates of alcohol 
use at both hospitals 
 
Among HAART-exposed women, more PI-exposed women (79%) had vaginal births than 
NVP (65%) and EFV-exposed (64%) women (P<0.001). This is consistent with JH hospital 
having more complicated pregnancies and deliveries than RM.  
 
The differences in prescribing protocols at the two hospitals could have affected the study 
outcomes. Women from JH tended to have more complicated pregnancies. They were more 
likely to be black, use alcohol (although rate of alcohol use in the whole cohort was extremely 
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low), have previous hypertension or diabetes, have increased gravidity and have had a 
previous miscarriage.  JH women also had a more advanced clinical stage of HIV than RM 
women. NVP and EFV were more likely to be prescribed at JH, so many of the same 
variables were more common in women on these regimens. The patient population of JH 
may have been prone to preterm deliveries for reasons other than their HAART regimen.  
 
4.3.3 Efavirenz exposure 
In this cohort, EFV-exposed women emerged as a distinct group with more risk factors for 
poor obstetric outcomes therefore higher rates of preterm birth and low birth weight infants 
than other regimens. A high percentage of EFV-based HAART exposed women were in 
WHO clinical stage 3 (61% of late HAART-exposed and 33% of early HAART-exposed) 
which was congruent with the preferred use of EFV in the presence of TB co-infection (WHO 
clinical stage 3 condition). The use of EFV in women with co-morbidity such as TB or liver 
disease, could also account for the lower median CD4 cell count and higher previous preterm 
birth rate detected in this group. However, when CD4 cell count, age and hypertension were 
controlled for, EFV use was no longer associated with LBW.  
.  
Among women exposed to late HAART, the duration of HAART exposure in weeks was 
similar for all regimens. Among women exposed to early HAART, the median weeks of 
exposure were much longer for EFV (62.7) than for PIs (17.1) or NVP (15.6). This indicates 
that a large number of women fell pregnant while on EFV but were only detected as pregnant 
after the first trimester. Although reassuring that none of the EFV-exposed infants in this 
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study had neural tube defects, EFV has been implicated as a potential teratogen in monkey 
studies [59-61] . Thus far in humans, four retrospective case of central nervous system 
defects in infants with first trimester exposure to EFV have been reported (three with 
meningomyelocele and one with a Dandy-Walker malformation) causing EFV to be changed 
from Pregnancy Category C to D [59, 62, 63] .The current antiretroviral prescribing guidelines 
allow for EFV to be prescribed to fertile women with adequate counselling about 
contraception [40]. In light of the many failures of contraception detected in this study, further 
study is necessary and these guidelines may need to be revised. 
 
4.4 ASSOCIATION OF VARIABLES WITH LOW BIRTH WEIGHT  
4.4.1 Variables associated with LBW 
The association of study variables was investigated among negative infants because positive 
infants are more likely to have LBW [48]. Once the infants with positive or unknown HIV 
status were removed, the following variables were found to be associated with LBW: 
 Maternal age 35 years or older 
 Maternal CD4 cell count below 100cells/mm3 
 Preterm infants 
 SGA infants 
 Early EFV exposure 
 Maternal HAART exposure >30 weeks or < 3 weeks 
 Maternal mixed ancestry 
 Advanced WHO clinical stage 
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 Maternal hypertension 
 
Many of these findings were in agreement with previous studies which have identified high 
maternal age, preterm birth, intrauterine growth restriction and maternal hypertension as risk 
factors for LBW [28]. After controlling for regimen type, CD4 cell count and maternal age, 
hypertension remained the variable most associated with LBW in the group of women 
exposed to early HAART.  
Contrary to previous studies, PI-exposure was not associated with LBW in early or late 
HAART-exposed women and seemed to be protective against LBW in the late group even 
after controlling for maternal CD4 cell count, age and hypertension. Additionally, in the early 
HAART group, nevirapine was found to decrease the odds of LBW. While residual 
confounding and biases stemming from missing data are important, the findings provide 
some certainty that exposure to early nevirapine, and early and late PI do not increase risk 
for LBW 
 
We found women with mixed ancestry to be associated with LBW which was different to 
previous US and European studies in which black race has been associated with LBW and 
preterm birth [28]. There were only eight women of mixed ancestry in this study group and it 
is possible that they represent a unique group that has not been studied for birth outcomes 
before. One South African study of women with mixed ancestry in the Cape, showed high 
infant mortality rates with LBW as a major contributing factor [64]. 
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HIV has also been associated with LBW and specific risk factors for LBW include low 
maternal CD4 cell count and advanced clinical stage [48]. Of note, in this cohort, low CD4 
cell count emerged as an important risk factor for both LBW and prematurity, with every gain 
of 50cells/mm3 being associated with significantly reduced risk of these adverse events. 
 
Women on HAART less than 3 weeks were associated with LBW because the duration of 
HAART was probably not long enough to impact foetal growth. This group was therefore 
similar to the HAART-unexposed group and had more SGA infants. Women on HAART more 
than 30 weeks were associated with LBW due to increased preterm births in this group. This 
is congruent with our previous finding that duration of HAART in pregnancy is directly related 
to preterm birth rate. 
 
4.4.2 Variables not associated with LBW 
The following variables were not associated with LBW: 
 Infant gender 
 Smoking 
 Alcohol use 
 Previous preterm birth 
 Previous miscarriage 
 Anaemia 
 Diabetes 
 Syphilis 
  124 
Previous studies have identified male gender as a risk for preterm birth and LBW [28]. In our 
study male and female infants were equally at risk for LBW.  Heavy alcohol use has been 
associated with LBW and preterm birth. In our study very few women used alcohol and the 
extent of alcohol use was not quantified but it is possible that alcohol use was not heavy 
enough to affect birth weight. Similarly smoking has been linked to preterm birth and LBW 
but it is possible that the number of smokers in our study were too few and /or the women did 
not smoke enough for it to pose a risk [28]. Unlike other studies, previous preterm birth, 
previous miscarriage, anaemia and syphilis were not associated with LBW but a trend of 
increased rate of LBW among RPR positive and severely anaemic women was detected [28, 
58]. It is possible that there were not enough women with these risk factors in our study to 
demonstrate these associations.  
 
4.5 LIMITATIONS 
Due to the retrospective nature of the study, there were gaps in the data obtained. The ANC 
ARV program was designed with the primary goal of clinical care, with observational 
research as a secondary component. Efforts are made to record all pertinent data and 
ensure follow-up, but data reflect the realities of our practice circumstance, with missing 
information on women who completed follow-up as well as a large number of women and 
infants lost to follow-up before infant HIV testing. Reportedly, pregnant women often come to 
Johannesburg for antenatal care but return to their homes at remote locations for infant 
delivery and often remain confined to their homes in the early postpartum period. 
Additionally, women face stigma, poverty, and fear about infant HIV diagnosis, all of which 
  125 
may serve as a deterrent to returning for 4-6 week infant testing and results. Linkage of 
antenatal and HIV services in the ANC-ARV clinic attempts to overcome some of these 
barriers, but retaining women in care remains a significant challenge. In this analysis we 
attempted to evaluate the influence of some missing data by performing comparisons among 
women with and without information on HAART duration. This analysis did not show 
differences in women who had information on HAART duration versus those that did not.  
 
Substantial gaps in data existed and analysis was restricted to subjects with complete data 
for each specific variable. This approach could have resulted in information bias and limits 
the external validity of our results.   
  
 Data on the WHO clinical stage was not collected for HAART-unexposed women. This is a 
limitation of the study because it would have been useful to compare the WHO clinical 
staging of HAART-exposed versus HAART-unexposed women. 
 
HIV viral load prior to delivery is a useful marker of adherence to HAART regimen and 
likelihood of transmission of the virus from mother to child [10]. This is not routinely collected 
in the study hospitals and was therefore not available for inclusion in the analysis.  
 
TB information was only available from JH women, most of these were on NVP-based 
regimens, and was therefore not a true reflection of the entire study group. Women exposed 
to early EFV-based HAART had the highest rates of TB because this regimen was used with 
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TB co-infection according to JH protocol. Any maternal infection poses a risk for intrauterine 
growth restriction and/or preterm birth [53, 65] and the incomplete TB data in this study is a 
limitation.  
 
Body mass index of women was also not available and this could have impacted LBW and 
preterm birth rate [23, 28].  
 
The study design meant that the group of HAART-unexposed women had received less 
antenatal care and had poorer health-seeking behaviour than their HAART-exposed 
counterparts which resulted in selection bias. This could have impacted the higher rate of 
LBW and SGA infants in the HAART-unexposed group but would not explain their lower rate 
of preterm births. 
 
The study hospitals served different communities with inherent differences. We attempted to 
negate some of these confounding factors in our analysis but acknowledge that some may 
still have impacted the study outcome. JH hospital, where more NVP-based and EFV-based 
HAART is used, has a more complicated patient base and this could have impacted the rates 
of preterm birth and LBW in these patients.  
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4.6 CLINICAL IMPLICATIONS  
HAART has been shown to reduce vertical transmission of HIV and improve maternal 
morbidity and mortality [3]. It is important to quantify its negative effect on birth outcomes in 
order to help patients make an informed decision about initiating HAART. Although we found 
an association between HAART and preterm birth, this risk was small and in this group of 
immunocompromised women no impact on birth weight was observed probably due to the 
protective effect of HAART on HIV-related intrauterine growth restriction. These findings 
should help reassure clinicians and HIV positive pregnant women that HAART is relatively 
safe in pregnancy.  
 
The morbidity and mortality benefits of initiating HAART before CD4 cell count decline to 
below 350cells/mm3 have been shown [66, 67]. A recent study based in South Africa showed 
that even in resource-limited settings, this approach  is cost-effective and beneficial to long-
term survival [68]. South Africa has recently followed this recommendation, and safe 
regimens have to be sought for pregnant women with CD4 cell counts between 250 and 350 
cells/mm3. Currently the South African PMTCT guidelines advocate NVP-based HAART 
regimens as the first line regimen for pregnant women [40,71]. Women who have contra-
indications to NVP due to resistance or adverse reactions are candidates for PI-based 
regimens. Additionally, NVP-based regimens have been associated with a ten fold increase 
in hepatic complications in women with CD4 cell counts above 250cells/mm3 [68, 69]. 
Concerns about the teratogenicity of exposure to EFV in the first trimester, limits it’s use to 
the second and third trimesters of pregnancy [49]. Concerns about the cost and risk of 
preterm delivery associated with PI-based regimens have made them less appealing. This 
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study suggests that in women with CD4 cell counts below 250cells/mm3, boosted PI-based 
regimens do not increase the risk of preterm delivery more than other types of HAART. 
Further study is necessary to investigate if this is true for pregnant women with CD4 cell 
counts between 250 and 350cells/mm3. 
 
Of note, in this cohort, low CD4 cell count emerged as an important risk factor for both LBW 
and prematurity. This finding highlights the importance of early HIV diagnosis and staging 
during pregnancy to accelerate HAART initiation in women who qualify. The recent South 
African guideline change [71] to increase the CD4 cell count treatment threshold to 350 
cells/mm3 may help minimise adverse pregnancy outcomes related to immune compromise.  
Further study is warranted so that consideration can be given to evaluating even higher CD4 
cell count thresholds, as increase in CD4 count is a modifiable factor that could reduce 
morbidity and mortality for both mothers and newborns.  
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CHAPTER 5 
 
5.0 CONCLUSIONS 
 
In this cohort of immunocompromised women HAART-exposure was associated with 
increased preterm birth between 34 and 37 weeks of gestation and a longer duration of 
HAART exposure increased this risk. This finding disproved the null hypothesis that HAART-
exposure was not associated with preterm birth. Exposure to PI-based regimens was not 
associated with preterm birth compared to NNRTI-based regimens. 
 
While HAART was associated with preterm birth, it was protective against low birth weight 
caused by HIV-induced intrauterine growth restriction. Immunocompromised HAART-
unexposed women had increased rates of SGA infants compared to their HAART-exposed 
counterparts. 
 
Low CD4 count emerged as an important modifiable risk factor for both LBW and preterm 
birth emphasizing the need for urgent HAART in women with low CD4 counts to boost 
maternal immunity and prevent adverse foetal outcomes.  
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These findings contribute to the limited knowledge about antenatal HAART-exposure in the 
African context. They reassure that the risk for adverse pregnancy outcomes attributable to 
HAART are small and likely to we outweighed by its protection against maternal and infant 
morbidity and mortality.  
 
Further study on the ideal gestation to initiate HAART in pregnant women who have no 
clinical indication for it, early enough to allow viral suppression and minimize mother to child 
transmission of HIV but late enough to decrease risk of preterm birth, would be useful. 
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APPENDIX 2 
 
Coronation Women and Children Hospital 
 
CONSENT FORM: USE OF CLINICAL INFORMATION  
This document must be explained to the patient/family member/guardian by a member of the clinical 
staff and a copy of the signed document is to be given to the patient/family member/guardian. 
 
Dear Guardian and Patient, 
 
You/your child are currently attending Coronation Hospital for treatment of problems you/your child 
are/is currently experiencing. The Hospital not only renders treatment but is also actively involved in 
conducting research aimed at improving the quality of care we deliver. From time to time such 
research involves the use of patient records from which information is extracted. The use of such 
information is subject to: 
 
1 Approval from the Committee for Research on Human Subjects (University of the 
Witwatersrand) 
 
2 Anonymity i.e. the identity of the patient from whose file information is extracted is never 
revealed to anyone but the researcher unless specific consent is obtained to do so. 
 
Whilst we are not currently involved in research that requires us to use any information now, this may 
change in the future when you are already discharged. We would like to obtain your consent to use 
information from your file for the purpose of research, subject to the aforementioned conditions. If you 
choose not to give consent, this will not compromise your treatment in any way. If at any time you 
choose to withdraw consent you are free to do so and will not be prejudiced in any way. 
Should you wish to contact us at any stage regarding this consent, contact Coronation Hospital at 
(011) 470 9424/9207. 
 
 
PATIENT NAME:…………………………………………………………………. 
 
A. 
I......................................................hereby give consent for my/my child’s records to be used as per the 
abovementioned conditions for the purposes of research: 
 
GUARDIAN NAME and RELATION:.......................................................................... 
 
SIGNATURE:………………………….. DATE:............................................... 
 
WITNESS:..............................................  DATE:.............................................. 
 
B. 
I.......................................................do not give consent for my/my child’s records to be used: 
 
GUARDIAN NAME and RELATION:……………………………………………….. 
 
SIGNATURE:........................................... DATE:............................................... 
 
WITNESS:................................................ DATE:................................................ 
